Journal articles on the topic '628.166 : 628.161.2'
To see the other types of publications on this topic, follow the link: 628.166 : 628.161.2.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic '628.166 : 628.161.2.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Buckingham, David. "Optical Properties: Modern Nonlinear Optics . Myron Evans and Stanisław Kielich, Eds. Wiley, New York, 1994. In three parts. Part 1, xii, 628 pp., illus. $150 or £124. Part 2, xii, 835 pp., illus. $195 or £161. Part 3, xiv, 823 pp., illus. $195 or £161. Advances in Chemical Physics, vol. 85." Science 266, no. 5185 (October 28, 1994): 665. http://dx.doi.org/10.1126/science.266.5185.665-a.
Full text
2
Buckingham, David. "Optical Properties: Modern Nonlinear Optics . Myron Evans and Stanisław Kielich, Eds. Wiley, New York, 1994. In three parts. Part 1, xii, 628 pp., illus. $150 or £124. Part 2, xii, 835 pp., illus. $195 or £161. Part 3, xiv, 823 pp., illus. $195 or £161. Advances in Chemical Physics, vol. 85." Science 266, no. 5185 (October 28, 1994): 665. http://dx.doi.org/10.1126/science.266.5185.665.a.
Full text
3
Jo, Hyung Ho, Young Ok Yoon, Jin Kyu Lee, and Shae K. Kim. "Effect of Partial Remelting Procedure on the Microstructural Evolution of 7075 Al Wrought Alloy for Thixoextrusion." Solid State Phenomena 116-117 (October 2006): 336–39. http://dx.doi.org/10.4028/www.scientific.net/ssp.116-117.336.
Full textAbstract:
The feasibility study for thixoextrusion of 7075 Al wrought alloys was carried out with respect to reheating profile, isothermal holding temperature and time during the partial remelting through simple partial remelting. The reheating rates were 40/min and 60/min. The isothermal holding temperatures were controlled at 609, 622, 628 and 632 for 0, 2, 5, 10 and 30 min. The interesting point of this study was that the thixotropic structures of 7075 Al wrought alloy without additional pretreatment could be obtained through simple partial remelting. The average grain size was significantly smaller in the quickly heated specimen. The liquid fraction was increased with increasing isothermal holding temperature and time while the average grain size was inversely proportional to isothermal holding temperature and time. However, there was no big change of liquid fraction and average grain size with respect to isothermal holding time. The important fact that the liquid fraction and average grain size were almost uniform after 5 min is considered very useful for thixoextrusion in terms of actual extrusion time.
4
KOOS, ROBERT D., and WILLIAM J. LEMAIRE. "The Effects of a Gonadotropin-Releasing Hormone Agonist on Ovulation and Steroidogenesis during Perfusion of Rabbit and Rat Ovariesin vitro*." Endocrinology 116, no. 2 (February 1985): 628–32. http://dx.doi.org/10.1210/endo-116-2-628.
Full text
5
Gschwandtner, Minar, Ahmadi, Haumer, Hülsmann, Maca, Schnürer, et al. "Therapeutische Alternativen in der Behandlung schwerer Beinischämien: Erfahrungen bei 190 Patienten an einer Klinischen Abteilung für Angiologie." Vasa 28, no. 4 (November 1, 1999): 271–78. http://dx.doi.org/10.1024/0301-1526.28.4.271.
Full textAbstract:
Background: Different therapies in consecutive patients (1987–1992) with chronic critical limb ischemia at a department of medical angiology, their short- and long-term outcome were investigated. Patients and methods: 190 patients (112 males, 78 females; age: 67 ± 12 years); 78 in grade II, 112 in grade III according to Rutherford’s classification. Therapeutic regimen: 1. vascular recanalisation by percutaneous transluminal angioplasty [PTA], local or systemic lysis; 2. surgical vascular reconstruction in case of impossibility or failure of catheter procedures; 3. prostanoids and/or antibiotics; 4. local wound treatment including amputations. Results: Vascular recanalisation was attempted in 156/190 (82.1%): PTA in 116/190, surgical vascular reconstruction in 50/190, local in 24/190 and systemic lysis in 8/190 patients. Prostanoids were applied in 89/190 and antibiotics in 73/190 patients. At the time of dismissal 164/190 (86.3%) patients were clinically improved; 11/190 (5.8%) unchanged, 13/190 (6.8%) had undergone major amputations and 2/190 (1.1%) had died. After 2,6 ± 2,2 years 77 of the 141 patients, who were still alive, were reexamined. Among these 77 patients 84.4% were in grade 0 or I, 15.6% in chronic critical limb ischemia. Furthermore 13.0% had been amputated since dismissal. Forty-nine of 190 (25.8%) patients had died 3,2 ± 1,9 years after dismissal from hospital. Conclusion: Catheter techniques, mostly PTA, is possible in the majority of patients with chronic critical limb ischemia. Cooperation with vascular surgeons in case of technical impossibility or failure of catheter recanalisation is mandatory. Such a regimen yields satisfactory short- and long-term results and a low rate of complications.
6
Salcedo, Irma. "Gerencia, una paradoja epistemológica." Revista de Ciencias Sociales 24, no. 3 (October 1, 2018): 130–32. http://dx.doi.org/10.31876/rcs.v24i3.24932.
Full text
7
Shimomura, Yoshimitsu, Masahiko Hara, Takaaki Konuma, Hidehiro Itonaga, Kazuteru Ohashi, Yukiyasu Ozawa, Tetsuya Eto, et al. "Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Myelodysplastic Syndrome in Adolescent and Young Adult Patients." Blood 132, Supplement 1 (November 29, 2018): 3452. http://dx.doi.org/10.1182/blood-2018-99-113275.
Full textAbstract:
Abstract nts Introduction Myelodysplastic syndrome (MDS) is clinically and biologically heterogeneous. Although the pathobiology of MDS is complex and not fully understood, the development of MDS involves a series of genetic changes, which influence hematopoietic growth and differentiation, resulting in the accumulation of abnormal cells and the impairment of normal hematopoiesis. Recently, Lindsley et al. reported the difference in the mutation of MDS genes in adolescent and young adult (AYA) patients and elder patients. These results suggested that MDS in AYA patients was biologically different from MDS in elderly patients. In addition, AYA patients have some specific issues such as infertility, late complications, and psychological and social problems. For AYA patients with MDS, similar to MDS patients of other age, allogeneic hematopoietic stem cell transplantation (HSCT) is the only curable treatment option. However, limited evidence was available indicating the effectiveness of allogeneic HSCT in the treatment of MDS in AYA patients, because about 90% of patients noted are usually in an older age group. Thus, we aimed to investigate the epidemiology of AYA patients with MDS who received allogeneic HSCT for the first time, and estimate prognostic factors after HSCT, using registry data of Japanese Data Center for Hematopoietic Cell Transplantation (JDCHCT). Methods We enrolled AYA patients aged 16-39 years from JDCHCT, who received allogeneic HSCT for the first time between January 2000 and December 2015. Active disease was defined as the presence of >5% blast in bone marrow and/or presence of blast in peripheral blood. We set the primary endpoint as the 5-year overall survival (5yOS). Five-year cumulative incidence of relapse (5yCIR) and 5-year cumulative incidence of non-relapse mortality (5yCINRM) were also evaluated as secondary endpoints. OS was evaluated using the log-rank test. Other endpoints were evaluated using Gray's method. To evaluate the prognostic factor for 5yOS, we employed the multivariable Cox proportional hazards model. Covariates were as follows: age (16-29 vs 30-39), sex (male vs female), Performance Status (PS) according to the Eastern Cooperative Oncology Group (0-1 vs 2-4), disease status (active vs non-active), karyotype risk according to the International Prognostic Scoring System (IPSS, good vs intermediate vs poor), conditioning regimen (Reduced intensity conditioning regimen [RIC] vs myeloablative conditioning regimen), donor type (related bone marrow transplantation [BMT] or peripheral blood stem cell transplantation [PBSCT] vs unrelated BMT or PBSCT vs cord blood transplantation [CBT]), prophylaxis of graft-versus-host disease (tacrolimus-based vs cyclosporine A-based), and years of HSCT (2000-2007 vs 2008-2015). Results We analyzed 628 AYA patients with MDS who received HSCT for the first time. Patient characteristics are described in Table 1. Median age was 30 years, 327 patients (52.7%) were of age ≥30 years, and 356 patients (56.7%) were male. At diagnosis, 140 patients (37.4%) were at IPSS low or intermediate-1 risk. At HSCT, 257 (40.9%) patients had active disease and 315 (52.1%), 166 (27.4%), and 124 (20.5%) patients had good, intermediate, and poor risk karyotype, respectively. RIC was administered for 121 (19.9%) patients. Regarding donor type, 230 (36.6%) received related BMT or PBSCT, 297 (47.3%) received unrelated BMT or PBSCT, and 101 (16.1%) received CBT. Regarding primary endpoint, 5yOS after allogeneic HSCT was 69.6% (65.6-73.2%) (Figure A). Five-year CIR and 5yCINRM were 11.9% (9.5-14.7%) and 20.7% (17.4-24.2%), respectively (Figure B, C). Regarding prognostic factors influencing 5yOS, active disease (adjusted hazard ratio [aHR]: 1.54, 95% confidence interval [95%CI]: 1.10-2.17, p-value = 0.013), poor karyotype (aHR: 2.06, 95%CI: 1.38-3.07, p-value < 0.001), PS 2-4 (aHR: 2.03, 95%CI: 1.19-3.48, p-value = 0.013), unrelated BMT or PBSCT (aHR: 2.10, 95%CI: 1.33-3.30, p-value = 0.001) and CBT (aHR: 2.40, 95%CI: 1.46-3.95, p-value < 0.001) were significantly associated with 5yOS, but other factors were not (Table 2). Conclusion In the present study, the epidemiology of AYA patients with MDS who received allogeneic HSCT for the first time, and the prognostic factors influencing 5yOS were evaluated. Our results provide physicians with additional information for the treatment of AYA patients with MDS. Disclosures Mori: Novartis Pharma: Research Funding; Astella Pharma: Honoraria; Shire Japan: Honoraria; Taisho Toyama Pharmaceutical Co: Honoraria; Japan Blood Products Organization: Honoraria; Eisai: Honoraria; Janssen: Honoraria; MSD: Research Funding; SHIONOGI: Honoraria; Pfizer: Honoraria; CHUGAI: Honoraria; Novartis Pharma: Honoraria; MSD: Honoraria; Ono: Honoraria; Celgene: Honoraria; Asahi Kasei: Research Funding; Kyowa Hakko Kirin: Honoraria. Tanaka:Bristol-Myers Squibb: Honoraria, Research Funding; Otsuka: Honoraria; Novartis Pharma: Honoraria; Pfizer: Honoraria. Ishiyama:Alexion Pharmaceuticals, Inc.: Honoraria.
8
Aryanti, Mira. "DETERMINAN BERAT BAYI LAHIR RENDAH (BBLR) DI RSUD INDRAMAYU KABUPATEN INDRAMAYU PROVINSI JAWA BARAT TAHUN 2016." JURNAL KESEHATAN INDRA HUSADA 5, no. 2 (April 18, 2018): 49–57. http://dx.doi.org/10.36973/jkih.v5i2.46.
Full textAbstract:
ABSTRAK
Berdasarkan data dari Dinas Kesehatan Provinsi Jawa Barat tahun 2012 menunjukan bahwa Angka Kematian Bayi (AKB) berjumlah 355 per 1.000 keahiran hidup. (Dinas Kesehatan Provinsi Jawa Barat, 2012).Berdasarkan data kasus jumlah kematian neonatal pada tahun 2014 berjumlah 257 kasus dengan BBLR 40,07 % kasus, asfiksia 23,73 % kasus, tetanus 0,77 % kasus, sepsis 5,83 % kasus, kelainan kongenital 11,67 % kasus, ikterus 1,55 % kasus dan lain-lain 16,34 kasus. Dan pada tahun 2015 dari bulan januari- Agustus 2015 jumlah kematian neonatal berjumlah 160 kasus dengan BBLR 42,5 % kasus, asfiksia 26,87 % kasus, sepsis 2,5 % kasus, kelainan kongenital 6,8 % kasus, ikterus 1,25% kasus, dan lain-lain 20 % kasus.Desain penelitian case control dengan perbandingan 1 : 2, populasi pada penelitian ini adalah semua ibu yang melahirkan bayi yang melahirkan di RSUD Indramayu. sampel penelitian adalah sebagian ibu yang melahirkan bayi berat lahir rendah periode Januari – Maret 2016 sebanyak 58 kasus dan kontrol 116. Pengolahan data menggunakan analisis univariat, uji chi-square dan multivariat (regresi logistik sederhana).Hasil penelitian yang dilakukan dengan melihat data rekam medic (data sekunder) pada 58 kasusdan 116 kontrol dengan metode acak sederhana, ditemukan bahwa factor dominan yang mempengaruhi kejadian BBLR di RSUD Indramayu adalah usia kehamilan dengan p value 0,000 dengan nilai OR 348,327 yang berarti bahawa usia kehamilan mempengaruhi kejadian BBLR sebanyak 348,3327 kali lebih beresiko setelah di control dengan variable lain.
9
Van der Heijde, D., L. S. Gensler, A. Deodhar, X. Baraliakos, D. Poddubnyy, A. Kivitz, M. K. Farmer, et al. "OP0105 EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 68–69. http://dx.doi.org/10.1136/annrheumdis-2020-eular.323.
Full textAbstract:
Background:Bimekizumab (BKZ), a monoclonal antibody that selectively neutralises interleukin (IL)-17A and IL-17F, is a potential therapeutic option in ankylosing spondylitis (AS).Objectives:To report 48-week (wk) patient-reported outcomes (PROs) in patients (pts) with AS treated with BKZ in a phase 2b dose-ranging study (BE-AGILE;NCT02963506).Methods:Pts with active AS (Bath AS Disease Activity Index [BASDAI] ≥4; spinal pain ≥4 [0–10]), fulfilling modified New York criteria (central reading), and inadequate response/intolerance to NSAIDs were randomised according to the study design (Figure 1). PROs included spinal pain, fatigue (BASDAI Q1), morning stiffness (mean of BASDAI Q5 + 6), Bath AS Functional Index (BASFI), Medical Outcomes Study (MOS) Sleep Problems Index II and AS Quality of Life questionnaire (ASQoL). Efficacy is reported for pts initially randomised to placebo (PBO) or BKZ 160/320 mg every 4 weeks (Q4W); treatment-emergent adverse events (TEAEs) are reported for pts who received ≥1 dose of study drug (Safety Set).Results:Of 303 pts, 181 were randomised to PBO or BKZ 160/320 Q4W mg at Wk 0; 179/181 completed Wk 12 and 161/181 completed Wk 48. At Wk 12, improvements in pain, fatigue, morning stiffness, BASFI, sleep and ASQoL were greater in BKZ pts vs PBO pts. Responses were further improved or maintained to Wk 48, with no meaningful differences between BKZ 160 mg and 320 mg (Table 1). Serious TEAEs occurred in 13/303 (4.3%) pts (Table 2), which included 2 major adverse cardiac events considered not related to study drug. Oral candidiasis occurred in 16 (5.3%) pts.Table 1.PRO efficacy endpoints to Week 48 (multiple imputation)Mean (SD)WkPBO – BKZ 160 mg(n=24)PBO – BKZ 320 mg(n=36)BKZ 160 mg(n=58)BKZ 320 mg(n=61)Spinal pain06.9 (1.4)7.0 (1.9)6.6 (2.0)7.3 (1.5)CfB12-1.5 (1.6)-0.7 (1.7)-2.6 (2.2)-3.6 (2.4)48-3.7 (2.0)-3.7 (2.6)-3.8 (2.4)-4.7 (2.1)Fatigue06.4 (1.7)6.8 (1.6)6.4 (1.7)6.4 (1.9)CfB12-0.7 (2.5)-1.0 (1.7)-2.1 (2.2)-2.1 (2.5)48-2.7 (2.2)-2.8 (2.4)-3.1 (2.1)-3.3 (2.4)Morning stiffness06.9 (1.7)6.7 (2.0)6.5 (1.8)6.6 (2.1)CfB12-1.5 (1.7)-1.1 (1.5)-2.8 (2.0)-3.4 (2.7)48-3.9 (2.2)-3.6 (2.4)-3.9 (2.2)-4.4 (2.4)BASFI05.8 (1.8)5.5 (2.2)5.5 (2.2)5.9 (2.0)CfB12-1.0 (2.1)-0.3 (1.7)-1.7 (1.8)-2.2 (2.0)48-2.9 (2.2)-2.4 (2.2)-2.5 (2.0)-2.9 (2.2)MOS Sleep Problems Index II045.5 (8.1)45.3 (7.9)46.9 (7.5)47.2 (9.4)CfB122.1 (8.3)1.8 (6.8)5.6 (6.7)6.8 (7.5)487.6 (8.7)8.0 (9.1)6.5 (6.1)8.0 (7.9)ASQoL08.4 (4.7)9.2 (4.7)8.4 (4.3)8.7 (4.3)CfB12-1.3 (5.5)-1.3 (3.7)-3.5 (4.3)-4.6 (4.8)48-4.2 (5.6)-5.3 (5.6)-4.9 (4.1)-5.4 (4.8)CfB: change from baselineTable 2.Overview of TEAEs to Week 48 (Safety Set; N=303)n (%)BKZ 160 mg(n=149)BKZ 320 mg(n=150)All BKZ [a](N=303)Any TEAE103 (69.1)122 (81.3)235 (77.6)Drug-related TEAEs48 (32.2)54 (36.0)110 (36.3)Serious TEAEs5 (3.4)6 (4.0)13 (4.3)Discontinuations due to TEAEs7 (4.7)10 (6.7)20 (6.6)[a] Includes TEAEs for 16 and 64 mg BKZConclusion:Pts with active AS demonstrated rapid and sustained improvements in PROs, sleep and quality of life over 48 wks of BKZ treatment. BKZ was generally well tolerated with no unexpected safety findings versus previous studies.Acknowledgments:This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.Disclosure of Interests:Désirée van der Heijde Consultant of: AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eisai, Eli-Lilly, Galapagos, Gilead Sciences, Inc., Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB Pharma; Director of Imaging Rheumatology BV, Lianne S. Gensler Grant/research support from: Pfizer, Novartis, UCB, Consultant of: AbbVie, Eli Lilly, GSK, Novartis, UCB, Atul Deodhar Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myer Squibb (BMS), Eli Lilly, GSK, Janssen, Novartis, Pfizer, UCB, Xenofon Baraliakos Grant/research support from: Grant/research support from: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Consultant of: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Speakers bureau: AbbVie, BMS, Celgene, Chugai, Merck, Novartis, Pfizer, UCB and Werfen, Denis Poddubnyy Grant/research support from: AbbVie, MSD, Novartis, and Pfizer, Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Alan Kivitz Shareholder of: AbbVie, Amgen, Gilead, GSK, Pfizer Inc, Sanofi, Consultant of: AbbVie, Boehringer Ingelheim, Flexion, Genzyme, Gilead, Janssen, Novartis, Pfizer Inc, Regeneron, Sanofi, SUN Pharma Advanced Research, UCB, Paid instructor for: Celgene, Genzyme, Horizon, Merck, Novartis, Pfizer, Regeneron, Sanofi, Speakers bureau: AbbVie, Celgene, Flexion, Genzyme, Horizon, Merck, Novartis, Pfizer Inc, Regeneron, Sanofi, Mary Katherine Farmer Employee of: UCB Pharma, Dominique Baeten Employee of: UCB Pharma, Nadine Goldammer Employee of: UCB Pharma, Jason Coarse Employee of: UCB Pharma, Marga Oortgiesen Employee of: UCB Pharma, Maxime Dougados Grant/research support from: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Consultant of: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Speakers bureau: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma
10
Barbosa, Patricia R., Sally P. Stabler, Mario H. Hirata, Rosario D. C. Hirata, Robert H. Allen, Luiz F. Sampaio-Neto, and Elvira M. Guerra-Shinohara. "Effects of Methionine Synthase (MS) A2756G and Methionine Synthase Reductase (MSR) A66G Polymorphisms on Methionine Metabolism in Brazilian Pregnant Women and Their Neonates." Blood 104, no. 11 (November 16, 2004): 3686. http://dx.doi.org/10.1182/blood.v104.11.3686.3686.
Full textAbstract:
Abstract Methionine synthase (MS) is a cobalamin dependent enzyme that catalyses the remethylation of homocysteine to methionine. The methionine synthase reductase (MSR) maintains adequate levels of methylcob(III)alamin, the activated cofactor for MS. The aim of this study was to investigate the effect of MS A2756G and MSR A66G polymorphisms on total homocysteine (tHcy), S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH) levels in 390 pregnant women and their 292 newborns, from Sorocaba city, Brazil. Genotypes of two polymorphisms were determined by PCR-RFLP. Pregnant women with MS 2756AA genotype have higher tHcy and lower Cbl levels than those with 2756G alleles. The MMA values were increased in neonates with MS 2756AA genotypes (Table 1). There are no difference between the maternal values of Cbl, serum folate, tHcy, MMA and SAM according to MSR A66G genotypes.The values of SAM were lower in neonates with MSR 66G alleles than those with AA genotypes (Table 2). We conclude that MS 2756AA genotypes are associated with higher tHcy levels in pregnant women and higher MMA levels in neonates. The MSR 66GG genotypes is associated with lower SAM levels in neonates. Table 1- Distribution of geometric means and confidence intervals 95% (CI 95%) and numbers of subjects for maternal and neonatal values of cobalamin (Cbl), serum folate, total homocysteine (tHcy), methymalonic acid (MMA) and S- adenosylmethionine (SAM) according to genotypes for the polymorphism MS A2756G. Variables Genotypes for MS A2756G Student t Test AA AG + GG Pregnant Women Cbl (pmol/L) 139 (133 – 144) 235 156 (146 – 166) 129 P= 0.001 SF (nmol/L) 14.3 (13.6 – 15.0) 234 14.5 (13.6 – 15.5) 129 P= 0.667 tHcy( μmol/L) 6.8 (6.5 – 7.1) 235 6.2 (5.9 – 6.6) 128 P= 0.036 MMA(nmol/L) 234 (219 – 245) 194 241 (219 – 265) 106 P= 0.610 SAM(nmol/L) 81.8 (77.9 – 86,0) 229 83.1 (79.1 – 87.4) 124 P= 0.663 Neonates Cbl (pmol/L) 227 (212 – 244) 188 234 (213 – 257) 101 P= 0.646 SF (nmol/L) 32.0 (31.0 – 33.0) 186 32.0 (30.8 – 33.2) 99 P= 0.967 tHcy μmol/L) 5.8 (5.5 – 6.1) 185 5.5 (5.1 – 5.9) 100 P= 0.229 MMA(nmol/L) 383 (364 – 402) 183 342 (317 – 369) 100 P= 0.011 SAM(nmol/L) 188 (181 – 196) 178 182 (168 – 197) 98 P= 0.491 Table 2 - Distribution of geometric means and confidence intervals 95% (CI (%%) and number of subjects for neonatal values of cobalamin (Cbl), serum folate, total homocysteine (tHcy), methylmalonic acid (MMA) and S- adenosylmethionine (SAM) according to genotypes for the polymorphism MSR A66G. Variables Genotypes MSR A66G Student t Test AA AG GG Groups not sharing a common superscript letter are significantly different at P<0.05 based on Tukey’s test Neonates Cbl (pmol/L) 225 (202 – 249) 86 229 (214 – 246) 166 247 (205 – 298) 35 P= 0.602 SF (nmol/L) 33.0 (31.6 – 34.4) 84 31.7 (30.7 – 32.7) 166 31.8 (29.7 – 34.2) 33 P= 0.352 tHcy μmol/L) ( 5.7 (5.3 – 6.2) 84 5.6 (5.3 – 5.9) 165 5.9 (5.3 – 6.6) 34 P= 0.618 MMA (nmol/L) 360 (334 – 389) 84 378 (357 – 400) 163 339 (299 – 384) 34 P= 0.230 SAM (nmol/L) 200 (186 – 215)a 82 184 (176 – 192)a 159 170 (149 – 195)b 33 P= 0.032
11
Shabanova, N. E., N. V. Korochanskaya, and A. I. Ponomareva. "ESTIMATION OF CLINICAL AND PHARMACOECONOMIC EFFICIENCY OF PROTON PUMP INHIBITORS DURING GASTROESOPHAGEAL REFLUX DISEASE (GERD) TREATMENT." Kuban Scientific Medical Bulletin 25, no. 6 (December 21, 2018): 160–63. http://dx.doi.org/10.25207/1608-6228-2018-25-6-160-163.
Full textAbstract:
Aim. The study was conducted to estimate the clinical and pharmacoeconomic efficiency of proton pump inhibitors (PPIs) omeprazole and esomeprazole when GERD patients undergo a course of medical treatment.Materials and methods. 25 GERD patients with a history of the disease for more than 5 years were under observation in Krasnodar regional clinical hospital № 2 from 2017 till 2018. All the patients have been thoroughly examined. Conservative therapy included the «gold standard» of proton pump inhibitors. Evaluation of the efficiency included the number of disease relapses in the period of dynamic observation and the calculation of the cost-effectiveness ratio.Results. When patients were taking esomeprazole, the relapses of the GERD disease were rare. The cost-effectiveness ratio was lower.Conclusion. The use of esomeprazole during the treatment of GERD patients has lower economic expenditures. The relapses of the disease are also less frequent.
12
Flayyeh, Thamer S. "A Comparison between High Ablative Versus Usual Dosages of Iodine-131 in Inducing Hypothyroidism After One Year of Therapy in Hyperthyroid Patients." AL-Kindy College Medical Journal 15, no. 2 (January 30, 2020): 18–22. http://dx.doi.org/10.47723/kcmj.v15i2.155.
Full textAbstract:
Background: Radioactive iodine-131 therapy is highly effective in treating patients with hyperthyroidism. An ablative dose is preferred by a number of endocrinologists, and, a fixed dose protocol seems to be better than a calculated dose in real practice.
Objective: To check for hypothyroidism in hyperthyroid patients one year after RAI therapy, comparing between the results of high ablative versus usual dosages of RAI-131.
Methods: This study included 174 hyperthyroid patients, 101 males and 73 females, divided into 2 groups, the first consisted of 162 patients given a usual fixed dose of RAI while the second consisted of 12 patients given a high fixed ablative dose of RAI. The study lasted about 2 years from August 2000 till July 2002 in the Specialized Centre for Endocrinology & Diabetes, Baghdad.
Results: Out of 162 patients in the first group, 11 patients (6.8%), developed hypothyroidism compared to 4 patients out of 12 (33.3% ) in the second group ( p < 0.05).
Conclusion: A high ablative dose RAI has a better outcome regarding hypothyroidism than a usual dose, although, endocrinologists have different opinions regarding this issue.
13
Corash, Laurence, Fabrice Cognasse, Jean-Claude Osselaer, Natalie Messe, and Olivier Garraud. "Release of Immune Modulation Factors from Platelet Concentrates during Storage after Photochemical Pathogen Inactivation." Blood 108, no. 11 (November 16, 2006): 941. http://dx.doi.org/10.1182/blood.v108.11.941.941.
Full textAbstract:
Abstract Background. Platelets (plt) prepared for transfusion contain multiple molecules that modulate immune function, mediate acute transfusion reactions, induce immune responses, and affect hemostasis. These cytokines/chemokines are secreted differentially from plt during storage (Transfusion2006;46:1184), and may be affected by processing, including pathogen inactivation. Aims. The INTERCEPT Blood System (IBS) for platelets utilizes amotosalen-HCl (S-59) with ultraviolet A (UVA) light to inactivate a broad spectrum of pathogens and leukocytes. This study was designed to evaluate the effects of photochemical treatment on in vitro release of immune modulation molecules after processing during 7 days (d) of storage. Methods. Platelet concentrates (n = 10) collected by aphaeresis (CPA) with process leuko-reduction (< 106) containing 8.15x1011 ± 0.8 platelets were suspended in 35% donor plasma and 65% platelet additive solution (Intersol, Baxter, France) and divided into two equal components. One served as an untreated control (C) and the other was prepared with 150 uM amotosalen and a 3 J/cm2 UVA photochemical treatment (PCT) and stored at 22°C with shaking for 7 days. Platelet concentration (106/uL), pH and levels of immune modulation factors were measured: CD62p(ng/mL), PDGF-AB(ng/mL), IL8(pg/mL), sCD40L(pg/mL), IL1β(pg/mL) and TNFα(pg/mL). The concentration of each factor was determined by specific enzyme linked immunosorbent assays in plt and supernatant (s) fractions isolated from stored PCT and C plt components. Mean values ± SD were calculated and compared by paired t-test. Results. Platelet content, pH and cytokine/chemokine content and release from CPA prepared with photochemical treatment were not statistically different (p > 0.05) from C during 7 d of storage (Table). From d1 to d7, the pH of PCT and C units decreased similarly, but remained within acceptable ranges. No detectable IL1β and TNFα were observed in PCT or C CPA. During platelet storage CD62p, PDGF-AB, IL8, and sCD40L increased similarly in supernatants of PCT and C units. The increase in supernatant levels correlated with a decrease of these cytokines in plt. Platelets in PCT and C retained measurable levels of CD62, IL8, sCD40L and PDGF-AB though 7 d. Levels of sCD40L demonstrated marked variation. Conclusions. Cytokines increased moderately in the supernatants of CPA and decreased in platelets during storage. After 7 d C and PCT platelets in CPA retained detectable levels of cytokines. PCT had no differential influence on release of immune modulation molecules in vitro over 7 d of storage. Day O O 5 5 7 7 Product C PCT C PCT C PCT pH 7.1 ±.1 7.1 ±.1 6.9 ±.1 6.8 ±.1 6.9 ±.1 6.8 ±.1 Plt ct 1.29 ±.3 1.30 ±.2 1.30 ±.3 1.19 ±.2 1.27 ±.2 1.18 ±.2 CD62p-s 89 ± 21 87 ± 17 110 ± 23 115 ± 27 117 ± 22 119 ± 25 CD62p-plt 149 ± 33 151 ± 33 141 ± 23 141 ± 25 139 ± 25 139 ± 26 PDGF-s 14.5 ± 3.5 13.6 ± 3.5 17.7 ± 2.4 15.8 ± 1.5 18.0 ± 2.1 17.5 ± 1.8 PDGF-plt 28.3 ± 3.5 30.3 ± 3.1 25.2 ± 3.6 24.9 ± 2.5 23.2 ± 4.0 23.3 ± 3.3 IL8-s 107 ± 17 108 ± 14 136 ± 42 116 ± 9 123 ± 20 120 ± 22 IL8-plt 135 ± 29 134 ± 28 110 ± 11 117 ± 12 103 ± 17 119 ± 32 CD40L-s 51 ± 86 66 ± 94 172 ± 157 237 ± 214 188 ± 198 201 ± 167 CD40L-plt 990 ± 805 1098 ± 747 485 ± 373 474 ± 331 346 ± 293 314 ± 282
14
Lim, Kar Keng, Muhammad Azmi Abd Hamid, Roslinda Shamsudin, Azman Jalar, and N. H. Al-Hardan. "Synthesis and Characterization of Grape-Like SnO2 Structures Grown by a Thermal Evaporation Method." Materials Science Forum 756 (May 2013): 48–53. http://dx.doi.org/10.4028/www.scientific.net/msf.756.48.
Full textAbstract:
Grape-like tin dioxide (SnO2) structures have been grown onp-type silicon (Si(100)) substrate synthesized by thermal evaporation of tin (Sn) without use of metal catalyst. The experiment were conducted in a three-zone tube furnace at a constant temperature of 1080°C,under 1.6% of oxygen (O2) gas in an atmospheric ambient with a controlled flow rate of 1.0L/min. The prepared SnO2film was characterized by using X-ray diffraction diffractometer (XRD), field emission scanning electron microscopy (FESEM), energy dispersive X-ray spectroscopy(EDX) and photoluminescence (PL) measurement. The grape-like SnO2structures were highly crystalline with particle size (resemble grape fruit) ranging from 120-550 nm and diameter of wire (resemble grape stem) around 120-160 nm.The PL spectrum of the grape-like SnO2structures exhibits a broad visible light emission with a peak centered at around 623 nm, corresponding to 1.99 eV and usual near band edge emission of SnO2is not observed.
15
Belal, Maymonah, Lori Villasis, Elizabeth Diago-Navarro, Michael Motley, Allen Young; Eric Spitzer, Bettina C. Fries, and Melinda Monteforte. "621. In vitro Ceftazidime: Avibactam Resistance in Carbapenem-Resistant Enterobacteriaceae Isolates." Open Forum Infectious Diseases 6, Supplement_2 (October 2019): S288—S289. http://dx.doi.org/10.1093/ofid/ofz360.689.
Full textAbstract:
Abstract Background Ceftazidime–avibactam (CAZ-AVI) is a new antibiotic with activity against many Carbapenem-resistant Enterobacteriaceae (CRE). Although CAZ-AVI resistance in CRE has been reported, it is not consistently assessed. Our study aimed to assess the prevalence of CAZ-AVI resistance in CRE isolated from patients with and without prior exposure to CAZ-AVI. Methods We tested 116 CRE isolates for CAZ-AVI resistance by Kirby–Bauer (KB) disk diffusion susceptibility. Resistant isolates were verified by repeat KB and E-test performed by the Stony Brook Hospital laboratory. The blaKPC gene of resistant strains was amplified by PCR and sequenced. Patient data were used to determine whether patients were colonized or infected, and whether they were exposed to CAZ-AVI. Results Of the 116 CRE isolates from 86 patients (96 encounters), 50% were Klebsiella species, 23.2% were Enterobacter species, 10.3% Escherichia coli and 16.5% other CRE. They were recovered from colonized (37%) and infected (63%) patients of which 18% were treated with CAZ-AVI during their hospitalizations (median duration of therapy, 6 days). Two CRE isolates (1.7%) were found to be resistant on repeated testing. One isolate was K. pneumoniae derived from the sputum of a patient diagnosed with ventilator-associated pneumonia who received 40 days of CAZ-AVI therapy prior to isolation of the resistant isolate (KB diameter 20 mm, MIC > 512 μg/mL by E-Test). Sequencing of the strain’s blaKPC3 gene revealed a previously described Ambler-position D179Y mutation that has been shown to convey resistance. The second CAZ-AVI-resistant K. pneumoniae (KB diameter 19 mm, MIC 64 μg/mL by E-test) was isolated from the urine of a colonized patient naïve to CAZ-AVI therapy. The strain’s blaKPC10 gene had no mutations. Conclusion In our strain collection, the rate of resistance to CAZ-AVI remains low <2%. Although we found one mutation (D179Y) previously linked to CAZ-AVI resistance we also discovered one K. pneumoniae isolate with in vitro resistance to CAZ-AVI that did not exhibit any blaKPC mutations conveying CAZ-AVI resistance. Interestingly, this strain was derived from a patient with no prior CAZ-AVI exposure. Whole-genome sequencing will be performed to identify other genes or mutations that may confer resistance. Disclosures All authors: No reported disclosures.
16
Pavlica, Ljiljana, Zorica Peric-Hajzler, Aleksandra Jovelic, Boris Sekler, and Milorad Damjanovic. "Psoriatic arthritis: A retrospective study of 162 patients." Vojnosanitetski pregled 62, no. 9 (2005): 613–20. http://dx.doi.org/10.2298/vsp0509613p.
Full textAbstract:
Aim. The aim of our study was to determine the prevalence of psoriatic arthritis in the patients with psoriasis and to analyze retrospectively the results of a 34-year multidisciplinary management of the patients with psoriatic arthritis. Methods. The study included 162 out of 183 treated patients with psoriatic arthritis, aged 48 ? 15 years. All the patients satisfied the current diagnostic criteria for psoriasis and psoriatic arthritis according to the American College of Rheumatology. Results. Psoriatic arthritis developed in 183 (9.3%) out of 1976 patients with psoriasis. Time interval for establishing the diagnosis was 4 years. A positive family history of the disease had 15.0% of the studied patients. Its onset was most often at 42 years of age in 70.4% of the cases, and 2 months to 59 years after the appearance of psoriasis. Psoriatic arthritis without psoriasis appeared in 1.8% of the patients. A severe form of arthritis had 64.2% of the patients, mainly the patients with scalp psoriasis (?2=3.2; p<0.05). Nail changes had 35% of the patients. Distal interphalangeal joints were involved in 63.6%, axial skeleton in 36.4%, oligoarthritis in 45.0%, polyarthritis in 55.0%, and mutilating form in 6.8% of the patients. Elevated Erythrocyte Sedimentation Rate was reveald in 61.7% of the patients. Immunoglobulin M (IgM) rheumatoid factor was altered in 4.3% of the patients. The human leukocyte antigen (HLA) typing in the 28 patients were: A2 32.0%, A3 18.0%, Al and A9 14.0%, A28 and A29 3.5%, B8 and B16 14.0%, B5 and B12 11.0%, B13,B15, B18, B27 and B35 7.0%. Radiologic changes were most often in hand and foot joints, less frequently in the knees and quite infrequently in hips and shoulders joints. Sacroiliitis was found in 46.4% of the patients. Psoriasis was treated with topical corticosteroids and salicylic ointments in all the patients, ultraviolet (PUVA therapy) in 5.6% and retinoids in 4.3% of them. Artrithis was treated with nonsteroidal anti-inflammatory drugs, with systemic corticosteroids 41.3% and with disease modified antirheumatic drugs, most frequently methotrexate, 59.9% of the patients. Radionuclide synovectomy was performed in 6.8%, surgery in 6.2% and physical therapy in all the patients. Conclusion. Psoriatic arthritis developed in 9.3% of the psoriatic patients. Time interval for establishing the diagnosis was long, and there were no specific laboratory findings. All the synovial joints could be involved in the psoriatic process. Scintigraphy should be used only in case of early suspected sacroiliitis. The treatment of psoriatic arthritis was the teamwork between the dermatologist, rheumatologist, physiatrist and orthopedic surgeon.
17
Swerdloff, Ronald S., and Robert E. Dudley. "A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men." Therapeutic Advances in Urology 12 (January 2020): 175628722093723. http://dx.doi.org/10.1177/1756287220937232.
Full textAbstract:
Background: A novel formulation of oral testosterone undecanoate (TU) was studied in a long- and short-term phase III trial to evaluate safety and efficacy. Methods: Hypogonadal men (age 18–65 years; two morning serum testosterone (T) <300 ng/dl with signs/symptoms) were recruited into a 365 day (trial I) or 105 day (trial II), randomized, multicenter trial. Patients were randomized 1:1 to oral TU ( n = 161) or T-gel ( n = 160) in trial I, and 3:1 to oral TU, twice daily (BID) JATENZO® ( n = 166) or a topical T product [Axiron® ( n = 56)] in trial II. Dose adjustments were based on average T concentrations ( Cavg). Efficacy was assessed based on T levels, body composition and bone density. Safety was assessed by standard clinical measures. Results: Oral TU efficacy (% of patients with eugonadal T Cavg) was 84% (serum Cavg = 628 ± 343 ng/dl) and 87% (serum T equivalent Cavg ≈ 489 ± 155 ng/dl) in trials I and II, respectively. Oral TU significantly ( p <0.0001) improved all Psychosexual Daily Questionnaire parameters in trials I and II. In trial I, lean mass increased 3.2 ± 2.7 kg and fat decreased by 2.4 ± 3.6 kg (both p <0.0001) and bone density improved in hip (+0.012 ± 0.0225 g/cm2) and spine (+0.018 ± 0.0422 g/cm2) after 365 days (both p <0.0001). Oral TU-associated adverse effects were consistent with other T-replacement therapies but oral TU patients experienced a greater number of mild gastrointestinal adverse effects. Oral TU subjects in both studies exhibited an increase in mean systolic blood pressure of about 3–5 mmHg. Oral TU was not associated with liver toxicity nor did it cause an elevation in high-sensitivity C-reactive protein or lipoprotein-associated phospholipase A2 (cardiovascular safety biomarkers) after 365 days of therapy. Conclusion: A new oral TU formulation was safe and effective and represents a significant therapeutic advance for the treatment of appropriate hypogonadal men.
18
Ghose, Abhimanyu, Harold Kunal Elias, Gunjan Guha, Mahender Yellu, Ria Kundu, and Tahir Latif. "Secondary CNS Relapse in DLBCL in the Rituximab Era - an Analysis of Prospective Studies." Blood 124, no. 21 (December 6, 2014): 1644. http://dx.doi.org/10.1182/blood.v124.21.1644.1644.
Full textAbstract:
Abstract INTRODUCTION CNS relapse in DLBCL carries poor prognosis. Some studies have suggested decreased incidence with rituximab, but there are several others reporting otherwise. We analyzed prospective studies in literature to understand the role of rituximab and CNS prophylaxis in DLBCL, in comparison to CHOP based therapy. METHOD Extensive searches using PUBMED, EMBASE, CENTRAL and major hematology conferences were conducted for prospective studies. The keywords CNS, diffuse large B-cell lymphoma, relapse, prophylaxis, rituximab, CHOP were used. Inclusion: (i) prospective or randomized trials (ii) Entire study population or a significant majority of patients were newly diagnosed DLBCL, (iii) no evidence of CNS involvement at baseline, (iv) use of rituximab-chemotherapy or CHOP-based chemotherapy, (v) have data relevant to our study. Exclusion: (i) retrospective studies, review article or case reports, (ii) exclusively testicular, mediastinal or double hit lymphoma, (iii) HIV positive patients. Data is presented as mean ± standard error of mean. Significant differences (at P<0.05) between groups and couplets were determined by one-way ANOVA and by two-tailed unpaired t-test respectively. Significance of the Kaplan-Meier survival curves was determined using Log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon tests. RESULTS The study population characteristics are shown in Table. The mean incidence of CNS relapse with rituximab-chemotherapy (R-CHOP/R-CHOEP) was found to be 5.52% (3.21%-7.73%), while that with CHOP-based chemotherapy alone was 4.43% (3.53% -5.33%). No significant difference was observed by two-tailed unpaired t test (P = 0.94). The median time from diagnosis to CNS relapse was 6.5-7 months. The mean incidence of leptomeningeal, parenchymal and both relapses in the rituximab-chemotherapy group were 38.62(±1.93)%, 57.32(±3.06)%, 5.36(±1.79)% compared to 16.17(±0.44)%, 66.17(±0.44)%, 22.06(±0.41)% with chemotherapy alone. One-way ANOVA also showed that use of rituximab resulted in statistically significant (P<0.0001) differences between the patterns of CNS relapse. About 74.1% of CNS relapses among patients receiving rituximab-chemotherapy were isolated CNS relapse, compared to 69.2% for those receiving CHOP chemotherapy. The mean incidence of CNS relapse with the use of any prophylactic CNS directed therapy was observed to be a significantly (P = 0.044) lower [2.97% (2.32%-3.62%)] compared to that without [6.12% (5.91%-6.335]. Median survival following CNS relapse of 365 days following rituximab based chemotherapy and 75 days after CHOP were significantly different (HR for CHOP use 4.867±0.77 at P<0.05). CONCLUSION Rituximab hasn't significantly decreased overall incidence, but causes less parenchymal CNS relapse. CNS prophylaxis has a definite role in high risk population. There is significantly better survival after CNS relapse in the rituximab era. Abstract 1644. TABLE STUDY Age (yr) Sex (M:F) No. Stage 3/4 IPI int-high/ high (>=3 IPI or >=2 aa IPI) Extranodal (>=2) high LDH Follow up (m) Criteria for CNS prophylaxis Patients receiving CNS prophylaxis (IT=intrathecal, S=systemic) Chemo Tilly 2003 61-69 ACVBP vs CHOP : M 182 vs 177 F 141 vs 135 635 (501 DLBCL) 267 vs 253 210 vs 207 (aa IPI) 155 VS 156 231 VS 241 68 None for CHOP VS ACVBP (IV methotrexate, etop + IT mtx) 323 (ACVBP) 323 ACVBP vs 312 CHOP Feugier 2004 69 M 92 (CHOP-R) vs 107 (CHOP) 202 vs 197 161 vs 157 121 vs 120 61 vs 51 131 vs 132 24 NA no prophylaxis 202 R-CHOP Vs 197 CHOP Bernstein 2009 97/ 225 for CHOP were >60 yrs NR 899 aggressive lymphoma 191/ 225 CHOP 95/ 225 CHOP 81/225 CHOP 146/ 225 CHOP 20 years none for CHOP 121 IT MTX or radiation (24 Gy) 225 CHOP vs ProMACE-CytaBOM vs mBACOD vs MACOP-B Boehme 2009 68 648 vs 569 1217 (944 DLBCL) 687 507 212 602 24 bone marrow, testes, sinuses, orbits, oral cavity, tongue, salivary glands. 475/1217 (IT-MTX) 608 RCHOP Vs 609 CHOP Kim 2012 59.5 NR 564 276 192 193 NR 10.5 ≥1 risk factor 59 IT RCHOP Kumar 2012 56 (prophylaxis) VS 58 (no prophylaxis) male: 74 vs 476 female: 43 vs 396 989 85 vs 454 55 vs 240 66 vs 220 57 vs 372 30 High risk site involvement : orbit, testis, peripheral blood, vertebra, bone marrow, nasal/paranasal sinuses 117/989 IT- 84/117 (AraC/MTX) S--33/117 (MTX) R-CHOP Holte 2013 54 97 vs 59 156 (145 DLBCL) 150 156 41 151 36 everyone 156/156 (S- Ara-c+ MTX) 1 dose of IT-MTX RCHOEP Figure 1 Figure 1. Figure 2 Figure 2. Disclosures No relevant conflicts of interest to declare.
19
Santos, Manoel Eduardo Rozalino, Dilermando Miranda da Fonseca, Valéria Pacheco Batista Euclides, Domicio do Nascimento Júnior, Augusto César de Queiroz, and José Ivo Ribeiro Júnior. "Características estruturais e índice de tombamento de Brachiaria decumbens cv. Basilisk em pastagens diferidas." Revista Brasileira de Zootecnia 38, no. 4 (April 2009): 626–34. http://dx.doi.org/10.1590/s1516-35982009000400006.
Full textAbstract:
Objetivou-se avaliar o efeito dos períodos de diferimento e de pastejo sobre a densidade populacional de perfilhos, a massa dos componentes morfológicos da forragem e o índice de tombamento em pastagens de Brachiaria decumbens cv. Basilisk. Dois ensaios foram conduzidos: o primeiro denominado ano 1 e, o segundo, ano 2. Adotou-se o esquema de parcelas subdivididas, segundo o delineamento em blocos casualizados, com duas repetições para cada combinação dos períodos de diferimento da pastagem com os períodos de pastejo. No ano 1, os períodos de diferimento foram 103, 121, 146 e 163 dias; e no ano 2, foram 73, 103, 131 e 163 dias. Os períodos de pastejo foram 1, 29, 57 e 85 dias. O aumento do período de diferimento elevou a densidade populacional de perfilhos reprodutivos (ano 2: de 37 para 304 perfilhos/m²) e reduziu a de perfilhos vegetativos (ano 1: de 1.253 para 889 perfilhos/m²; ano 2: de 1.235 para 627 perfilhos/m²). Durante o período de pastejo, ocorreu diminuição no número de perfilhos vegetativo (ano 1: de 988 para 868 perfilhos/m²) e reprodutivo (ano 1: de 216 para 0 perfilhos/m²; ano 2: de 203 para 0 perfilhos/m²) e aumento no número de perfilhos mortos (ano 1: 463 para 1.088 perfilhos/m²; ano 2: de 341 para 1.010 perfilhos/m²). Pastagens sob maiores períodos de diferimento e de pastejo apresentaram maior massa de colmo morto (6.093 e 3.819 kg/ha de MS nos anos 1 e 2, respectivamente) e menor massa de lâmina foliar verde (341 e 177 kg/ha de MS nos anos 1 e 2, respectivamente). Pastos de Brachiaria decumbens cv. Basilisk, submetidos a longos períodos de diferimento e de pastejo possuem características estruturais desfavoráveis à produção animal.
20
PERTCEVA, G. M., A. A. BORSCHEVA, and E. E. KUDINOVA. "COURSE OF PREGNANCY AND CHILDBIRTH OF A WOMAN WITH ACHONDROPLASIA." Kubanskij nauchnyj medicinskij vestnik 1, no. 2 (January 1, 2017): 163–65. http://dx.doi.org/10.25207/1608-6228-2017-2-163-165.
Full text
21
Алиев, Озбек Мисирхан, Сабина Телман Байрамова, Дильбар Самед Аждарова, Валида Мурад Рагимова, and Шарафат Гаджиага Мамедов. "Синтез и свойства синтетического айкинита PbCuBiS3." Kondensirovannye sredy i mezhfaznye granitsy = Condensed Matter and Interphases 22, no. 2 (June 25, 2020): 182–89. http://dx.doi.org/10.17308/kcmf.2020.22/2821.
Full textAbstract:
Целью данной работы является синтез и исследование свойств синтетического айкинита, PbCuBiS3.Синтез проводили в откачанных кварцевых ампулах в течение 7–8 ч, максимальная температура составляла 1250–1325 К. Далее образцы охлаждали и выдерживали при 600 К в течение недели. Потом ампулы вскрывали, образцы тщательно перетирали и после плавки отжигали при 600–800 К в зависимости от состава не менее двух недель для приведения образцов в равновесное состояние. Отожженные образцы исследовали методами дифференциально-термического (ДТА), рентгенофазового (РФА), микроструктурного (МСА) анализов, а также измерением микротвердости и определением плотности. РФА проводили на рентгеновском приборе модели Д 2 PHASER с использованием CuKa- излучении Ni-фильтр.Комплексом методов физико-химического анализа изучены разрезы CuBiS2–PbS, Cu2S–PbCuBiS3, Bi2S3–PbCuBiS3, PbBi2S4–PbCuBiS3, PbBi4S7–PbCuBiS3 квазитройной системы Cu2S–Bi2S3–PbS и построены их фазовые диаграммы.Установлено, что кроме сечения PbBi2S4–PbCuBiS3 все разрезы квазибинарные и характеризуются наличием ограниченных областей растворимости на основе исходных компонентов.При изучении разреза CuBiS2–PbS установлено образование четверного соединения состава PbCuBiS3, встречающееся в природе в виде минерала айкинита, плавящегося конгруэнтно при 980 К. Установлено, что соединение PbCuBiS3 кристаллизуется в ромбической сингонии с параметрами решетки: а = 1.1632, b = 1.166, с = 0.401 нм, прост. группа Pnma, Z = 4. Методами ДТА и РФА установлено, что соединение PbCuBiS3 является фазой переменного состава с областью гомогенности от 45 до 52 мол. % PbS. Соединение PbCuBiS3 является дырочным полупроводником с шириной запрещенной зоны ΔЕ = 0.84 эВ.
ЛИТЕРАТУРА
1. Zhang Y-X., Ge Z-H., Feng J. Enhanced thermoelectric properties of Cu1.8S via introducing Bi2S3 andBi2S3/Bi core-shell nanorods. Journal of Alloys and Compounds. 2017;727: 1076–1082. DOI: https://doi.org/10.1016/j.jallcom.2017.08.2242. Mahuli N., Saha D., Sarkar S. K. Atomic layer deposition of p-type Bi2S3. Journal of Physical ChemistryC. 2017;121(14): 8136–8144. DOI: https://doi.org/10.1021/acs.jpcc.6b126293. Ge Z-H, Qin P., He D, Chong X., Feng D., Ji Y-H., Feng J., He J. Highly enhanced thermoelectric propertiesof Bi/Bi2S3 nano composites. ACS Applied Materials & Interfaces. 2017;9(5): 4828–4834. DOI: https://doi.org/10.1021/acsami.6b148034. Savory C. N., Ganose A. M., Scanlon D. O. Exploring the PbS–Bi2S3 series for next generation energyconversion materials. Chemistry of Materials. 2017;29(12): 5156–5167. DOI: https://doi.org/10.1021/acs.chemmater.7b006285. Li X., Wu Y, Ying H., Xu M., Jin C., He Z., Zhang Q., Su W., Zhao S. In situ physical examination of Bi2S3 nanowires with a microscope. Journal of Alloys and Compounds. 2019;798: 628–634. DOI: https://doi.org/10.1016/j.jallcom.2019.05.3196. Patila S. A., Hwanga Y-T., Jadhavc V. V., Kimc K. H., Kim H-S. Solution processed growth andphotoelectrochemistry of Bi2S3 nanorods thin fi lm. Journal of Photochemistry & Photobiology, A: Chemistry.2017;332: 174–181. DOI: https://doi.org/10.1016/j.jphotochem.2016.07.0377. Yang M., Luo Y. Z., Zeng M. G., Shen L., Lu Y. H., Zhou J., Wang S. J., Souf I. K., Feng Y. P. Pressure inducedtopological phase transition in layered Bi2S3. Physical Chemistry Chemical Physics. 2017;19(43):29372–29380. DOI: https://doi.org/10.1039/C7CP04583B8. Kоhatsu I., Wuensch B. J. The crystal structure of aikinite, PbCuBiS3. Acta Crystallogr. 1971;27(6):1245–1252. DOI: https://doi.org/10.1107/s05677408710038199. Ohmasa M., Nowacki W. A redetermination on the crystal structure of aikinite (BiS2/S/S/CuIVPbVII).Z. Krystallogr. 1970;132(1-6): 71-86. DOI: https://doi.org/10.1524/zkri.1970.132.1-6.7110. Strobel S., Sohleid T. Three structures for strontium copper (I) lanthanidis (III) selinidesSrCuMeSe3 (M = La, Gd, Lu). J. Alloys and Compounds. 2006;418(1–2): 80–85. DOI: https://doi.org/10.1016/j.jallcom.2005.09.09011. Сикерина Н. В., Андреев О. В. Кристаллическая структура соединений SrLnCuS3(Ln = Gd, Lu).Журн. неорган. химии. 2007;52(4): 641–644. Режим доступа: https://www.elibrary.ru/item.asp?id=959411112. Edenharter A., Nowacki W., Takeuchi Y. Verfeinerung der kristallstructur von Bournonit [(SbS3)1/CuPbPb2IV VIIVIII] und von seligmannit [(AsS3)2/CuPbPb2IVVIIVIII]. Z. Kristallogr. 1970;131(1): 397–417.DOI: https://doi.org/10.1524/zkri.1970.131.1-6.39713. Каплунник Л. Н. Кристаллические структуры минералов великита, акташита, швацита, теннантита, галхаита, линдстремита-крупкаита и синтетической Pb, Sn сульфосоли. Автореф. дисс. … канд.геол.-минер. наук. М.: Изд-во Моск. ун-та; 1978. 25 с.Режим доступа: https://search.rsl.ru/ru/record/0100780541514. Гасымов В. А., Мамедов Х. С. О кристаллохимии промежуточных фаз системы висмутинайкинит (Bi2 S3–CuPbBiS3). Азерб. хим. журн.1976;(1): 121–125. Режим доступа: https://cyberleninka.ru/article/n/fazovye-ravnovesiya-v-sisteme-pbla2s4-pbbi2s415. Christuk A. E., Wu P., Ibers J. A. New quaternary chalcogenides BaLnMQ3 (Ln – Rare Earth; M = Cu, Ag;Q = S, Se). J. Solid State Chem. 1994;110(2): 330–336. DOI: https://doi.org/10.1006/jssc.1994.117616. Wu P., Ibers J. A. Synthesis of the new quaternary sulfi des K2Y4Sn2S11 and BaLnAgS3 (Ln = Er, Y, Gd)and the Structures of K2Y4Sn2S11 and BaErAgS3. J. Solid State Chem. 1994;110(1): 156–161. DOI: https://doi.org/10.1006/jssc.1994.115017. Победимская Е. А., Каплунник Л. Н., Петрова И. В. Кристаллохимия сульфидов. Итоги наукии техники. Серия кристаллохимия. М.: Изд-во АН СССР. 1983; 17: 164 с.18. Gulay L. D., Shemet V. Ya., Olekseyuk I. D. Investigation of the R2S3–Cu2S–PbS (R = Y, Dy, Ho andEr) systems. J. Alloys and Compounds. 2007;43(1–2): 77–84. DOI: https://doi.org/10.1016/j.jallcom.2006.05.02919. Костов И., Миначева-Стефанова И. Сульфидные минералы. М.: Мир; 1984. 281с. 20. Алиева Р. А., Байрмаова С. Т., Алиев О. М. Диаграмма состояния систем CuSbS2–PbS (M = Pb,Eu, Yb). Неорган. материалы. 2010;46(7): 703–706. DOI: https://doi.org/10.1134/s002016851007002221. Байрамова С. Т., Багиева М. Р., Алиев О. М., Рагимова В. М. Синтез и свойства структурныханалогов минерала бурнонита. Неорган. материалы. 2011;47(4): 345–348. DOI: https://doi.org/10.1134/S002016851104005422. Байрамова С. Т., Багиева М. Р., Алиев О. М. Взаимодействие в системах CuAsS2–PbS. Неорган.материалы. 2011;47(3): 231–234. DOI: https://doi.org/10.1134/S002016851103004623. Aliev O. M., Ajdarova D. S., Bayramova S. T., Ragimova V. M. Nonstoichiometry in PbCuSbS3. Azerb.chem. journal. 2016;(2): 51–54. Режим доступа: https://cyberleninka.ru/article/n/nonstoichiometryin-pbcusbs3-compound24. Aliev O. M., Ajdarova D. S., Agayeva R. M., Ragimova V. M. Phaseformation in quasiternary systemCu2S–PbS–Sb2S3. Intern Journal of Application and Fundamental Research. 2016;(12): 1482–1488. Режимдоступа: https://applied-research.ru/pdf/2016/2016_12_8.pdf25. Алиев О. М., Аждарова Д. С., Агаева Р. М., Максудова Т. Ф. Фазообразование на разрезахCu2S(Sb2S3, PbSb2S4, Pb5Sb4S11)–PbCuSbS3 квазитройной системы Cu2S–Sb2S3–PbS и физические свой-ства твердых растворов (Sb2S3)1–x(PbCuSbS3)x. Неорган. материалы. 2018;54(12): 1275–1280. DOI: https://doi.org/10.1134/S002016851812001426. Рзагулуев В. А., Керимли О. Ш., Аждарова Д. С., Мамедов Ш. Г., Алиев О. М. Фазовые равновесия в системах Ag8SnS6–Cu2SnS3 и Ag2SnS3–Cu2Sn4S9. Конденсированные среды и межфазныеграницы. 2019; 21(4): 544–551. DOI: https://doi.org/10.17308/kcmf.2019.21/2365
22
Rammos, G., A. Panutsopoulos, K. Xynos, E. Koufogeorga, V. Peppes, K. Kostopoulos, and P. Turli. "Hyponatremia and Selective Serotonin Reuptake Inhibitors." European Psychiatry 24, S1 (January 2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70746-1.
Full textAbstract:
Aims:Hyponatremia (HPN) is a potentially lethal electrolytic disturbance. Certain medical treatments are integrated in the etiology of that sodium disorder. We retrospectively studied the rate of HPN in patients examined in the emergency room (ER) of Alexandra Hospital receiving a selective serotonin reuptake inhibitor (SSRI).Methods:17,410 patients, 55.54% women and 44.46% men were examined in the ER over a one year period. 281 patients (1,61% of total) presented with HPN, 162 were women (57.6%) and 121 (42.3%) men. Plasma Sodium values ≤ 133mEq/l defined HPN. 13 of the 281 patients with HPN (4.6%) with no renal, heart or hepatic impairment were on an SSRI regimen.Results:11 of 162 women (6.8%) presented with HPN were receiving concurrently SSRI and either thiazide diuretic (3 ) or furosemide (2 ). 2 of 121 men (1.65%) were on SSRI regimen and furosemide. SSRI dosage was in all cases within suggested therapeutic limits. Table 1 demonstrates mean values and standard deviation of all the parameters examined.PatientsAgePlasma Na+Plasma K+Plasma CreatininePlasma UreaHct1366,9 +/- 17,4 years127,2 +/- 6,1 mEq/4 +/- 0,7 mEq/l1.06 +/-0,5 mg%39,8 +/- 16,2 mg%36,7 +/ 2,9%Conclusion:SSRI therapy presents a potential cause for HPN principally in women older than 65 years old with increasing risk when diuretic is used concomitantly. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and expression conversion of aquaporin-2 receptors of the collecting ducts are two possible pathophysiologic mechanisms of HPN occurrence.
23
LÝ, NGỌC-SÂM, THOMAS HAEVERMANS, and HANS-JUERGEN TILLICH. "Aspidistra quangngaiensis, a new species of Asparagaceae from Vietnam." Phytotaxa 312, no. 1 (July 4, 2017): 123. http://dx.doi.org/10.11646/phytotaxa.312.1.11.
Full textAbstract:
The genus Aspidistra Ker Gawler (1822: 628) contains more than 160 species in tropical and subtropical SE-Asia, with the centre of species diversity in southern China and adjacent northern Vietnam (Tillich 2005, 2014, Tillich & Averyanov 2012, Vislobokov et al. 2013). In Vietnam, the genus has more than 50 species with many locally endemic taxa, and about 2/3 of them were discovered from limestone areas in north Vietnam, while ca. 1/3 of species were recently described from sandstone forests in the southern part of the country (Gagnepain 1934, Bogner & Arnautov 2004, Bräuchler & Ngoc 2005, Tillich 2005, 2006, 2008, Tillich et al. 2007, Tillich & Averyanov 2008, 2012, Tillich & Leong-Škorničková 2013, Averyanov & Tillich 2012, 2013, 2014, 2015, 2016a, 2016b, Leong-Škorničková et al. 2014, Colin 2015, Averyanov et al. 2016, Vislobokov 2015, Vislobokov et al. 2013, 2014a, 2014b, 2016a, 2016b, Lý & Tillich 2016, 2017).
24
Masarova, Lucia, Naval Daver, Naveen Pemmaraju, Prithviraj Bose, Sherry Pierce, Taghi Manshouri, Jorge E. Cortes, Hagop M. Kantarjian, and Srdan Verstovsek. "Do Patients with Post-Essential Thrombocythemia and Post-Polycythemia Vera Differ from Patients with Primary Myelofibrosis?" Blood 126, no. 23 (December 3, 2015): 4069. http://dx.doi.org/10.1182/blood.v126.23.4069.4069.
Full textAbstract:
Abstract Introduction: Clinical characteristics of post-essential thrombocythemia/polycythemia vera myelofibrosis "post ET/PV-MF" are not well defined as for primary myelofibrosis "MF". Objective: We aimed to identify morphological, clinical and prognostic characteristics of patients with post ET/PV-MF seen at our center. Methods: Retrospective chart review of 1120 patients with MF - 766 primary MF, 354 post ET/PV-MF, who were referred to our institution between years 1984-2013 was performed; 92% presented after the year of 2000. Fisher's exact and Mann-Whitney test were used for categorical and continuous variables; Cox proportional hazard model and Kaplan-Meier curves with log rank test for correlation between the variables and survival. Survival analysis were calculated after censoring patients for stem cell transplantation "SCT" (n=92). Results: Overall median follow up was 36 months (0-411), 51% (n=573) patients had died. Progression to AML after median time of 32 months was not different between groups and occurred in 9.5% (n=106) patients over observation period of 5180 persons-years. Incidence rate was 3.4 cases per 100 persons-year. Causes of death were known in 55% of patients, and included progression of MF in 38% (n=122), infection in 27% (n=86), and other reasons with less than 10% occurrence (complications post SCT; secondary malignancy; other medical conditions). Demographics and disease characteristics are depicted in a table. 92% of patients were evaluable for karyotype; abnormalities were detected in 39% (n=404), of which 53% were unfavorable with monosomal (23%), complex (43%) and trisomy 8 (18%) being the most common. Molecularly high risk mutations "MHR" in genes ASXL1, EZH2, and IDH1/2 were positive in 35% of tested patients (n=161) regardless of presence of driver mutation. IPSS and DIPSS plus scores were similar between MF and post ET/PV-MF (with IPSS low in 8.7%, intermediate 1 in 19%, intermediate 2 in 28%, and high in 44%). By multivariate analysis, higher risk categories of IPSS and DIPSSplus predicted shorter overall survival "OS" for both cohorts (by DIPSSplus - high risk: HR 2.7, 95% CI 2.1-3.5; int-2: HR 1.6; 95% CI 1.3-2.0). Median OS stratified by IPSS was 160 (HR 1.8, 95%CI 1.0-3.0), 116 (HR 1.5, 95%CI 1.0 -1.5), 78 (HR 1.4, 95%CI 1.2-1.7) and 54 months, p=0.001. Univariate analysis identified age over 65, anemia, trombocytopenia, leukopenia, increased blasts, splenomegaly, constitutional symptoms, unfavorable karyotype, JAK2 mutation and triple negativity as predictors for inferior survival. Age over 65; hemoglobin below 10, platelets below 100 and peripheral blasts ≥1% showed significance for predicting OS by multivariate analysis. When stratified according to diagnosis, higher age, anemia, thrombocytopenia, high blasts, JAK2 positivity and triple negativity retained prognostic significance for MF whereas anemia, thrombocytopenia, and JAK2 mutation for post ET/PV-MF. Median OS was 73 months (range, 0.1-210) without difference between MF and post ET/PV-MF. Conclusion: Post ET/PV-MF does not appear to have substantial different clinical characteristics than primary MF. Table. Characteristics Total, number or median (% or range) MF, number or median (% or range) PET/PV-MF, number or median (% or range) Age 65 (20-89) 64 (20-88) 64 (27-89) Age > 65 552 (49) 367 (48) 185 (53) Males 675 (60%) 494 (65) 181 (51)* WBC 9.6 (0.4-361) 17.3 (5-19) 16.7 (5-18) WBC > 24 203 (18) 133 (18) 70 (20) WBC < 4 160 (14) 130 (17) 30 (8.5)* Plt 204 (3-2690) 237 (1-1364) 354 (6-2690)* Plt < 100 276 (25) 220 (29) 56 (16)* Hgb 10.5 (5-18) 10 (5-18) 11 (5-19)* Hgb < 10 462 (42) 329 (43) 133 (38)* Transfusion dependency 265 (24) 203 (27) 62 (18)* Blasts ≥ 1% 523 (47) 371 (49) 152 (43) Splenomegaly 668 (60) 459 (63) 209 (65) Symptoms 793 (71) 537 (70) 256 (73) LDH 1246 (189-10343) 1248 (189-10353) 1261 (205-8476) LDH > 620 958 (86) 640 (85) 318 (90)* JAK2 positive 586 (57) 371 (63) 215 (37)* MPL positive 19 (1.9) 16 (84) 3 (16)* CARL positive 53 (5) 27 (51) 26 (49)* Triple negative 26 (2.5) 21 (81) 5 (19)* *statistically significant differences (p<0.05) Disclosures Pemmaraju: Stemline: Research Funding; Incyte: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; LFB: Consultancy, Honoraria. Cortes:Novartis: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Teva: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; ARIAD Pharmaceuticals Inc.: Consultancy, Research Funding.
25
Barreira, S. C., A. R. Cruz-Machado, A. L. Fernandes, I. Genrinho, G. Sequeira, P. Monteiro, and J. E. Fonseca. "AB1145 PRESCRIPTION PATTERNS AND DISEASE ACTIVITY IN PORTUGUESE WOMEN OF CHILDBEARING AGE WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND JUVENILE IDIOPATHIC ARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1862.1–1863. http://dx.doi.org/10.1136/annrheumdis-2020-eular.1976.
Full textAbstract:
Background:Disease activity (DA) at conception is one of the main predictors of pregnancy outcomes in women of childbearing age (WoCBA) with rheumatic diseases. Teratogenicity and unawareness about pregnancy compatibility of some disease-modifying anti-rheumatic drugs might limit the choice of treatment in WoCBA.Objectives:To assess differences in prescription patterns between WoCBA with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and juvenile idiopathic arthritis (JIA) and comparator groups, namely postmenopausal women (PMW) and age-matched men. Evaluate DA in WoCBA comparing to the aforementioned groups.Methods:Observational transversal study, using data from the portuguese registry of rheumatic diseases (Reuma.pt) from 3 portuguese centers. Adult patients (pts) with the diagnosis of RA, PsA, AS or JIA were allocated to the following groups: WoCBA (aged 18–44y), young men (YM) (18–44y), PMW (≥ 45y) and matched men (≥45y). Demographic and clinical variables are described as means or frequencies. Differences between groups regarding therapy and DA were assessed with Chi-square and ANOVA tests. Linear and logistic regression models were used to find predictors of DA and prescription patterns.Results:2133 pts were included, 69.9% female with a mean age of 55.96±15.85 y. 1437 pts were diagnosed with RA, 305 with PsA, 254 with AS and 137 with JIA. Patterns of prescription are detailed in table 1. WoCBA were less likely to be treated with glucocorticoids than PMW (OR 0.66 95%CI 0.44-0.99). WoCBA were 1.76 times more likely to be treated with MTX than YM (95%CI 1.04-2.97). Certolizumab was specially prescribed in WoCBA (OR 13.8, 95%CI 1.4-132.8). WoCBA had significantly higher DA scores than YM (DAS28 3.03±1.39 vs 2.32±1.18 and BASDAI 3.55±2.0 vs 2.43±1.66).Table 1.Prescription patternsMedications, n (%)A -WoCBA(N=256)B - Young Men(N=161)C - Post menopausal Women(N=927)D - MenN=340Chi-square testNSAIDs143 (55.9)111(68.9)472 (50.9)169 (49.7)p<0.001Glucocorticoids106 (41.4)31 (19.3)625 (67.4)154 (45.3)p<0.001csDMARDs- Methotrexate149 (58.2)60 (37.3)663 (71.5)197 (57.9)p<0.001- Leflunomide12 (4.7)4 (2.5)45 (4.9)2 (0.6)p=0.003- Sulfassalazine9 (3.5)5 (3.1)39 (4.2)9 (2.7)NS- Hydroxychloroquine36 (14.1)4 (2.5)117 (12.6)18 (5.3)p<0.001bDMARDs- Etanercept48 (18.8)29 (18.0)140 (15.1)66 (19.4)NS- Infliximab9 (3.5)11 (6.8)36 (3.9)30 (8.8)p=0.002- Adalimumab17 (6.6)15 (9.3)47 (5.1)27 (7.9)NS- Golimumab15 (5.9)18 (11.2)37 (4.0)30 (8.8)p<0.001- Certolizumab10 (3.9)0 (0)2 (0.3)2 (0.6)p<0.001- Tocilizumab12 (4.7)2 (1.2)71 (7.7)10 (2.9)p<0.001- Rituximab5 (1.9)0 (0)50 (5.4)4 (1.2)p<0.001- Abatacept0 (0)0 (0)9 (1)0 (0)NS- Secukinumab1 (0.4)4 (3.5)8 (0.9)2 (0.6)NS- Ustekinumab1 (0.4)3 (1.9)5 (0.5)0 (0)NStsDMARDs4 (1.6)1 (0.6)9 (0.9)0 (0)NSbDMARDs – biologic disease modifying antirheumatic drugs, csDMARDs – conventional synthetic disease modifying antirheumatic drugs, NSAIDs – non-steroidal anti-inflammatory drugs, tsDMARD – targeted synthetic disease modifying antirheumatic drugs, WoCBA – women of childbearing ageConclusion:Certolizumab was prescribed preferentially in WoCBA, who alsoreceived more MTX than YM. Nevertheless, DA in this group was not well controlled, which may influence future pregnancy outcomes. Ensuring tight DA control in WoCBA through proper and ideally no teratogenic medication remains an unmet clinical need.Disclosure of Interests:None declared
26
Busscher, Henk J., Betsy van de Belt-Gritter, Rene J. B. Dijkstra, Willem Norde, Fernanda C. Petersen, Anne A. Scheie, and Henny C. van der Mei. "Intermolecular Forces and Enthalpies in the Adhesion of Streptococcus mutans and an Antigen I/II-Deficient Mutant to Laminin Films." Journal of Bacteriology 189, no. 8 (February 2, 2007): 2988–95. http://dx.doi.org/10.1128/jb.01731-06.
Full textAbstract:
ABSTRACT The antigen I/II family of surface proteins is expressed by most oral streptococci, including Streptococcus mutans, and mediates specific adhesion to, among other things, salivary films and extracellular matrix proteins. In this study we showed that antigen I/II-deficient S. mutans isogenic mutant IB03987 was nearly unable to adhere to laminin films under flow conditions due to a lack of specific interactions (0.8 × 106 and 1.1 × 106 cells cm−2 at pH 5.8 and 6.8, respectively) compared with parent strain LT11 (21.8 × 106 and 26.1 × 106 cells cm−2). The adhesion of both the parent and mutant strains was slightly greater at pH 6.8 than at pH 5.8. In addition, atomic force microscopy (AFM) experiments demonstrated that the parent strain experienced less repulsion when it approached a laminin film than the mutant experienced. Upon retraction, combined specific and nonspecific adhesion forces were stronger for the parent strain (up to −5.0 and −4.9 nN at pH 5.8 and 6.8, respectively) than for the mutant (up to −1.5 and −2.1 nN), which was able to interact only through nonspecific interactions. Enthalpy was released upon adsorption of laminin to the surface of the parent strain but not upon adsorption of laminin to the surface of IB03987. A comparison of the adhesion forces in AFM with the adhesion forces reported for specific ligand-receptor complexes resulted in the conclusion that the number of antigen I/II binding sites for laminin on S. mutans LT11 is on the order of 6 × 104 sites per organism and that the sites are probably arranged along exterior surface structures, as visualized here by immunoelectron microscopy.
27
LOGIN, IVAN S., ALLAN M. JUDD, MICHAEL J. CRONIN, KOJI KOIKE, GENNARO SCHETTINI, TAKESHI YASUMOTO, and ROBERT M. MACLEOD. "The Effects of Maitotoxin on45Ca2+Flux and Hormone Release in GH3 Rat Pituitary Cells*." Endocrinology 116, no. 2 (February 1985): 622–27. http://dx.doi.org/10.1210/endo-116-2-622.
Full text
28
TSYMBALYUK, I. Y., A. M. MANUILOV, K. A. POPOV, F. U. KHUBIEVA, and E. E. GILEVA. "THE BIOLOGICAL ACTIVITY OF SODIUM DICHLOROACETATE AND ITS EFFECTIVENESS DURING THE EXPERIMENTAL CLINICAL STUDIES." Kubanskij nauchnyj medicinskij vestnik 1, no. 2 (January 1, 2017): 151–62. http://dx.doi.org/10.25207/1608-6228-2017-2-151-162.
Full text
29
Kim, Johnny S., Becci A. Akin, and Jody Brook. "Solution-focused brief therapy to improve child well-being and family functioning outcomes with substance using parents in the child welfare system." Developmental Child Welfare 1, no. 2 (March 5, 2019): 124–42. http://dx.doi.org/10.1177/2516103219829479.
Full textAbstract:
This study examined the effectiveness of solution-focused brief therapy (SFBT) on child well-being and family functioning outcomes for child welfare involved parents. A randomized controlled trial design was used to evaluate the effectiveness of SFBT as compared to treatment-as-usual in an outpatient substance abuse treatment center. Mixed linear models tested within and between-group changes using intent-to-treat analysis ( N = 180). Hedges’s g effect sizes examined the magnitude of treatment effects. Both conditions reported improvements on the child well-being measures (Behavior Rating Inventory of Executive Function [BRIEF]-Parent Report and Child Behavior Checklist-School Age Form [CBCL-SA]) and family functioning measures (Adult-Adolescent Parenting Inventory [AAPI-2] and Center for Epidemiologic Studies-Depression [CES-D] Short Form) at posttest. While none of the between group analyses were statistically significant on either outcome domains, effect sizes did show improvements in the small to medium range for both groups. SFBT effect sizes for BRIEF subscales ranged from .024 to .267 and for control group ranged from .136 to .363. SFBT effect sizes on CBCL-SA subscales ranged from .059 to .321 and for control group ranged from .101 to .313. SFBT effect sizes on AAPI-2 subscales ranged from .006 to .620 and control group ranged from .023 to .624. SFBT effect sizes on CES-D measure were .428 and for control group were .317. Results show SFBT to be an effective intervention for helping parents around child well-being and family functioning outcomes similar to current empirically-supported therapies. SFBT provides a more strengths-based approach to help families improve family well-being and thus help improve their child’s well-being.
30
Iwasaki, Yasumasa, Yutaka Oiso, Hidehiko Saito, and Joseph A. Majzoub. "Positive and Negative Regulation of the Rat Vasopressin Gene Promoter*." Endocrinology 138, no. 12 (December 1, 1997): 5266–74. http://dx.doi.org/10.1210/endo.138.12.5639.
Full textAbstract:
Abstract To study the transcriptional regulation of the vasopressin gene in vitro, 3 kb of the 5′ regulatory region of the rat vasopressin gene was isolated and subcloned, along with a series of various deletion mutants, into vectors containing the luciferase reporter gene. After transfecting these genes transiently into the human choriocarcinoma cell line JEG-3 along with a glucocorticoid receptor (GR) expression vector, transcriptional activity was quantitated using the luciferase assay. Forskolin, 8-bromo-cAMP, and protein kinase A catalytic subunit expression all markedly increased transcription from the 3-kb promoter. Analyses with deletion mutants of the promoter showed that two cAMP-responsive element (CRE)-like sequences (−227 to −220 bp and −123 to −116 bp) contribute to this positive regulation. Expression of KCREB, a dominant negative mutant of the cAMP-responsive element binding protein (CREB), suggested the involvement of CREB. Transfection of the activator protein 2 (AP2) DNA consensus sequence partially blocked transcription. Dexamethasone suppressed forskolin-stimulated expression. The negative effect of glucocorticoid was GR dependent and may be mediated by a mechanism not involving GR binding to DNA because it was independent of the putative glucocorticoid-responsive element previously reported in the vasopressin promoter (−622 to −608 bp) and was preserved in the shorter promoter constructs in which no glucocorticoid-responsive element-like sequence was found. Our data suggest that several trans-acting factors including CREB, AP2, and GR are likely to be involved in vasopressin gene transcription and that the positive and negative regulation of vasopressin gene transcription is complex.
31
Igawa, T., K. Ichinose, M. Okamoto, A. Takatani, N. Yajima, K. E. Sada, R. Yoshimi, et al. "AB0413 INVESTIGATION OF THE ASSOCIATION OF CARDIOVASCULAR EVENTS AND ANTI- SS-A ANTIBODIES AS RISK OF DEVELOPMENT IN PATIENTS WITH LUPUS NEPHRITIS FROM THE LUNA REGISTRY: A CROSS-SECTIONAL STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1507.1–1507. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4047.
Full textAbstract:
Background:Cardiovascular disease(CVD) has been identified as a major cause of morbidity and mortality in patients with lupus nephritis(LN)1) 2). There is a clear causal relationship between the onset of neonatal lupus (cardiac complications) and SS-A antibodies3) 4), but no association has been reported in adults. In recent years, there have been reports from overseas that suggest the association between CVD and anti-SS-A antibody in adult systemic lupus erythematosus (SLE) patients5) 6). So far, no studies have not been reported to evaluate the relationship between anti-SS-A antibody and the risk of developing CVD in LN in a large cohort of patients with SLE in Japan.Objectives:The aim of this study was to evaluate the association between anti-SS-A antibody and the risk of developing CVD in LN patients using a multicenter registration study [Lupus registry of nationwide institution (LUNA)] in Japan.Methods:We identified 931 patients diagnosed with SLE in the Lupus registry of nationwide institution (LUNA), and further identified 275 LN patients with known the presence or absence of both development of CVD and presence of anti-SS-A antibody. We defined the exposure factor as anti-SS-A antibody, and the outcome as CVD. SELENA-SLEDAI score (at diagnosis), eGFR <60%, HbA1c, BMI, and steroid pulse treatment history were used as confounding factors and we analyzed using logistic regression analysis.Results:We found 68 patients (24.7%) complicated with CVD, including percarditis (7.3%), cerebrovascular disorder (6.2%), peripheral Arterial Disease (6.2%), Ischemic heart disease (2.9%),venous thromboembolism (2.9%),pulmonary hypertension (1.5%), vulvular heart disease (1.1%), and cardiomyopathy (0.4%). In univariate analysis, there was no significant difference in the occurrence of CVD depending on the presence or absence of anti-SS-A antibody (p = 0.32), and the results of multivariate analysis showed no significant difference in anti-SS-A antibody [p = 0.23, odds: 0.41, 95% confidence interval (0.09-1.89)].Conclusion:The association between anti-SS-A antibody and the development of CVD in LN patients in Japan has not been identified.References:[1]Lupus. 2000;9(3):166-9[2]Arthritis Rheum.2019 Mar;71(3):403-410,[3]J Intern Med 265:653-662, 2009[4]Nat Clin Pract Rheumatol 5:139-148, 2009[5]Ann Rheum Dis 1990;49:627-629[6]Chest. 2018 Jan;153(1):143-151. Doi:Disclosure of Interests:None declared
32
Beppu, Naohito, Hidenori Yanagi, Naoki Yamanaka, Hiroshi Doi, Norihiko Kamikonya, Masafumi Noda, and Naohiro Tomita. "Acceptance of sphincter-preserving surgery for T3 lower rectal cancer after short-course radiotherapy with delayed surgery." Journal of Clinical Oncology 32, no. 3_suppl (January 20, 2014): 620. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.620.
Full textAbstract:
620 Background: One of the reasons for avoiding sphincter-preserving surgery for lower rectal cancer is difficulty in obtaining a sufficient distal margin. Short-course radiotherapy (SRT) with immediate surgery is not expected to reduce tumor volume, and currently available evidence suggests that it does not increase the sphincter-preservation rate. However, SRT with delayed surgery has been linked to downsizing of the primary tumor during the waiting period. We evaluated the feasibility of sphincter-preserving surgery for T3 lower rectal cancer after SRT with delayed surgery and examined whether a distal margin of ≤ 5 mm has an impact on oncologic outcomes. Methods: We retrospectively studied 161 consecutive patients with lower rectal cancer located below the peritoneum reflection who underwent radical surgery with total mesorectum resection (TME) 3 to 4 weeks after the completion of SRT. The median follow-up was 53.5 months. Results: Sphincter-preserving surgery was performed in 149 (92.5%) of the 161 patients. The procedures were as follows: double-stapling technique, 58 patients; intersphincteric resection, 91; abdominoperineal resection, 10; and Hartmann operation, 2. Among the patients who underwent sphincter-preserving surgery, the distal margin was ≤ 5 mm in 41 patients and > 5 mm in 108. The local recurrence rate was respectively 5.8% vs. 10.4% (p = 0.606), the recurrence-free survival 83.4% vs. 82.8% (p = 0.682), and the overall survival at 5 years 82.3% vs. 87.6% (p = 0.418). Our results suggested that there is no difference in long-term outcomes between a distal margin of ≤ 5 mm and > 5 mm. Conclusions: Sphincter-preserving surgery was performed in 92.5% of patients with T3 lower rectal cancer who received SRT with delayed surgery. Our results confirmed the long-term oncologic feasibility of sphincter-preserving surgery with a distal margin of ≤ 5 mm; there was no negative impact on long-term outcomes such as local recurrence, recurrence-free survival, and overall survival.
33
Morales-Ancajima, Valeria C., Cinthya Vasquez-Velasquez, Melany De la Cruz, Maria Marull, Vilma Tapia, and Gustavo F. Gonzales. "The social isolation enforced by the COVID-19 pandemic reduces the Health-Related Quality of Life score in the adult population of Metropolitan Lima, Peru." F1000Research 11 (April 12, 2022): 415. http://dx.doi.org/10.12688/f1000research.109836.1.
Full textAbstract:
Background: The objective of this study was to determine the association between health-related quality of life (HRQoL) in adults in Metropolitan Lima, Peru, with experienced social isolation during the coronavirus disease 2019 (COVID-19) pandemic regardless of if the person was infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adjusted by age, sex and body mass index (BMI). Methods: This cross-sectional study evaluated 256 men and 382 women living in Metropolitan Lima, who were administered the Health-Related Quality of Life (HRQoL) questionnaire (SF-20) virtually to assess their health-related quality of life. Results: Obesity (beta coefficient, 95%CI [95% confidence interval]: -262 – -116), female sex (beta coefficient, 95%CI: -151 – -59), the longest time of mandatory social confinement (beta coefficient, 95%CI: -6.8 – -0.2), and the existence of chronic disease (beta coefficient, 95%CI: -147 – -44) were associated with a low total score of the HRQoL questionnaire. Conclusions: Mandatory social confinement may have harmed the perception of health-related quality of life.
34
O’Sullivan, Ian, Ádám Tibor Schlégl, Péter Varga, Kamilla Kerekes, Csaba Vermes, and Péter Than. "Csontkor – a csontrendszeri érettség mérésének lehetősége EOS készülékkel." Orvosi Hetilap 160, no. 16 (April 2019): 619–28. http://dx.doi.org/10.1556/650.2019.31337.
Full textAbstract:
Abstract: Introduction: Hand and wrist bone age assessment methods cannot be performed when using the recommended patient position within the EOS scanner. Aim: We aimed to assess alternative methods for use with the EOS. Method: After investigating 9 alternatives, five methods were selected – cervical vertebra (Hassel–Farman), iliac crest (Risser ‘plus’), hip (Oxford), knee (O’Connor), calcaneus (Nicholson) – and applied to EOS scans of 114, 2–21-year-old normal individuals. Intraclass correlation coefficient tests for reliability and Spearman correlation with calendar age were assessed. Results: Intra- and interobserver reliabilities were all excellent, except with the knee method (0.865 – ‘good’). Calcaneal and cervical methods were the fastest to apply (mean 17.5 s, 33.4 s per evaluation), however, calcanei were unassessable in 14% of scans (versus 1% of cervical). All methods correlated significantly with calendar age (r>0.829, p<0.05). Difficulties were principally absent (12%) or obscured (23%) landmarks. Conclusion: Bone age assessment is possible with all 5 methods, however, the Hassel–Farman method proved to be easily useable, fast and reliable. Orv Hetil. 2019; 160(16): 619–628.
35
Byeon, Kyeongmin, Hye Ree Kim, Seung-Jung Park, Young Jun Park, Ji-Hoon Choi, Ju Youn Kim, Kyoung-Min Park, Young Keun On, and June Soo Kim. "Initial Experience with Left Bundle Branch Area Pacing with Conventional Stylet-Driven Extendable Screw-In Leads and New Pre-Shaped Delivery Sheaths." Journal of Clinical Medicine 11, no. 9 (April 28, 2022): 2483. http://dx.doi.org/10.3390/jcm11092483.
Full textAbstract:
Until recently, left bundle branch area pacing (LBBAp) has mostly been performed using lumen-less fixed screw leads. There are limited data on LBBAp with conventional style-driven extendable screw-in (SDES) leads, particularly data performed by operators with no previous experience with LBBAp procedures. In total, 42 consecutive patients undergoing LBBAp using SDES leads and newly designed delivery sheaths (LBBAp group) were compared with those treated with conventional right ventricular pacing (RVp) for atrioventricular block (RVp group, n = 84) using propensity score matching (1:2 ratio). The LBBAp was successful in 83% (35/42) of patients, with satisfactory pacing thresholds (0.8 ± 0.2 V at 0.4 ms). In the LBBAp group, the mean paced-QRS duration obtained during RV apical pacing (173 ± 18 ms) was significantly reduced by LBBAp (116 ± 14 ms, p < 0.001). Compared with the RVp group, the LBBAp group showed more physiological pacing, suggested by a much narrower paced-QRS duration (116 ± 14 vs. 151 ± 21 ms, p < 0.001). The pacing threshold was comparable in both groups. The LBBAp group revealed stable pacing thresholds for 6.8 ± 4.8 months post-implant and no serious complications including lead dislodgement or septal perforation. The novel approach of LBBAp using SDES leads and the new dedicated pre-shaped delivery sheaths was effectively and safely performed, even by inexperienced operators with LBBAp procedures.
36
Wang, Chang-Sheng, Wan-Ting Lin, Yeong-Jene Chiang, and Ching-Yuh Wang. "Metabolism of Fluazifop-P-butyl in Resistant Goosegrass (Eleusine indica) in Taiwan." Weed Science 65, no. 2 (March 2017): 228–38. http://dx.doi.org/10.1017/wsc.2016.35.
Full textAbstract:
Fluazifop-P-butyl, a selective graminicide, has been widely used to control annual grass weeds for more than three decades in Taiwan, and a resistant (R) biotype of goosegrass has consequently appeared. In this study, liquid chromatography/tandem mass spectrometry (LC/MS/MS) was applied to analyze metabolites of fluazifop-P-butyl in a R biotype of goosegrass. Six signals, including mass-to-charge ratios (m/z) 512, 432, 423, 415, 314, and 160, in positive scanning mode, and four signals, including m/z 788, 623, 593, and 162, in negative scanning mode, were found in the metabolites of the R and S biotypes, respectively. All of the signals of these metabolites in the R biotype showed higher intensity than those of the S biotype, except for m/z 162. Based on the molecular weights of the fragments (MS2 signal) from the molecules (MS1 signal) and comparison with the Metabolite Link Metabolomics database, MassBank database, and related references, one reduced form of fluazifop acid, i.e., 2-[4-(5- trifluoromethyl-2-pyridyloxy) phenoxy] propanol (MW 313); two types of intermediates of MW 163, i.e., 5-trifluoromethyl-2-pyridone and 5-trifluoromethyl-2-hydroxypyridine (or 2-hydroxy-5-trifluoromethyl pyridine); and five possible conjugated compounds containing a common core fragment (MW 255) from fluazifop acid were identified. In addition, another compound, likely degraded from one of the five conjugated compounds, was also detected. Accordingly, the metabolic pathway of fluazifop-P-butyl in goosegrass is described in this study. An enzyme kinetic study on glutathione S-transferase showed that the R biotype has higher affinities to the substrates reduced glutathione (GSH) and 1-chloro-2, 4-dinitrobenzene, with S/R Km ratios of 3.0 and 2.4, respectively. No difference in Vmax was found, revealing that the S biotype has a strong ability to bind GSH and herbicide or target molecules and showed susceptibility to fluazifop.
37
SOOD, P. C., M. SAINATH, and K. VENKATARAMANIAH. "EXCEPTIONAL STRUCTURES IN THE ODD-ODD NUCLEUS 250Md." International Journal of Modern Physics E 09, no. 04 (August 2000): 309–17. http://dx.doi.org/10.1142/s0218301300000258.
Full textAbstract:
The low-energy two-quasiparticle bandhead energies for the odd-odd Z=101 nucleus 250 Md are evaluated using a zero range residual neutron-proton interaction. The 250Md ground state is seen to have the spin-parity Iπ=0- corresponding to the singlet band from the configuration {p : 7/2[514]⊗n:7/2[624]} in violation of the Gallagher-Moszkowski (GM) coupling rule. The situation here is shown to be almost identical to that for the rare-earth nucleus 166 Ho , which is the only well-established exception to the GM rule known so far. Analysis of the expected low energy spectrum, including the rotational levels, for 250 Md reveals the occurrence of an as-yet-unobserved long-lived high-spin Iπ = 7- isomeric state around (80±30) keV with dominant ε and α decay modes.
38
Novomlinsky, V. V. "The Use of Laser Technology and Aquacomplex Titanium Glitserosolvat in the Treatment of Chronic Osteomyelitis." Vestnik of Experimental and Clinical Surgery 9, no. 2 (June 19, 2016): 156. http://dx.doi.org/10.18499/2070-478x-2016-9-2-156-164.
Full textAbstract:
Хронический остеомиелит остается одной из наиболее сложных проблем гнойной хирургии, что связано, в том числе, с вы-сокой частотой встречаемости, составляющей до 6% в структуре патологии опорно-двигательной системы и 6,8–12% вструктуре гнойно-септических заболеваний, высоким риском развития септических осложнений и рецидивов, инвалидиза-ции, достигающей 55% случаев.Целью исследования явилось улучшение результатов лечения хронического остеомиелита путем применения лазерныхтехнологий и аквакомплекса глицеросольвата титана.Материалы и методы. Экспериментальные исследования проведены в 5 группахна 175 белых крысах с хроническим остео-миелитом: 2-х контрольных и 3-х опытных. 1-ю контрольную группу составили животные без лечения. Во 2-й контрольнойи опытных группах проводилась хирургическая санация гнойного очага. В 1-й опытной группе санация костной полостибыла дополнена применением низкоинтенсивного лазерного облучения. Во 2-й опытной группе выполнялось введение в кост-ную полость аквакомплекса глицеросольвата титана. В 3-й опытной группе – обработка костной полости низкоинтен-сивным лазерным излучением с последующим введением в нее аквакомплекса глицеросольвата титана. В ходе выполненияработы применяли клинические,гематологические, микробиологические и рентгенологические методы исследования.Результаты и их обсуждение. Моделирование хронического остеомиелита по разработанной методике позволяло к 31-мсуткам сформировать патологический процесс со свищами с гнойным отделяемым, что подтверждалось данными клини-ческих, микробиологических и рентгенологических исследований.Выводы Разработанный метод комплексного лечения хронического остеомиелита, основанный на сочетанном примене-нии лазерных технологий и аквакомплекса глицеросольвата титана способствовал сокращению сроков закрытия раневогодефекта, нормализации общего состояния и двигательной активности; нормализации окружности бедра поврежденнойконечности, показателей свободнорадикального окисления.
39
Reiche, Edna Maria Vissoci, Ana Maria Bonametti, Maria Angélica Ehara Watanabe, Helena Kaminami Morimoto, Arilson Akira Morimoto, Susana Lilian Wiechmann, José Wander Breganó, Tiemi Matsuo, and Fernando Vissoci Reiche. "Socio-demographic and epidemiological characteristics associated with human immunodeficiency virus type I (HIV-1) infection in HIV-1-explosed but uninfected individuals, and in HIV-1-infected patients from a southern brasilian population." Revista do Instituto de Medicina Tropical de São Paulo 47, no. 5 (October 2005): 239–46. http://dx.doi.org/10.1590/s0036-46652005000500001.
Full textAbstract:
The ability to control human immunodeficiency virus type 1 (HIV-1) infection and progression of the disease is regulated by host and viral factors. This cross-sectional study describes the socio-demographic and epidemiological characteristics associated with HIV-1 infection in 1,061 subjects attended in Londrina and region, south of Brazil: 136 healthy individuals (Group 1), 147 HIV-1-exposed but uninfected individuals (Group 2), 161 HIV-1-infected asymptomatic patients (Group 3), and 617 patients with AIDS (Group 4). Data were obtained by a standardized questionnaire and serological tests. The age of the individuals ranged from 15.1 to 79.5 years, 54.0% and 56.1% of the Groups 3 and 4 patients, respectively, were men. The major features of groups 2, 3, and 4 were a predominance of education level up to secondary school (55.8%, 60.2% and 62.4%, respectively), sexual route of exposure (88.4%, 87.0% and 82.0%, respectively), heterosexual behavior (91.8%, 75.2% and 83.7%, respectively), and previous sexually transmitted diseases (20.4%, 32.5%, and 38.1%, respectively). The patients with AIDS showed the highest rates of seropositivity for syphilis (25.6%), of anti-HCV (22.3%), and anti-HTLV I/II obtained by two serological screening tests (6.2% and 6.8%, respectively). The results documenting the predominant characteristics for HIV-1 infection among residents of Londrina and region, could be useful for the improvement of current HIV-1 prevention, monitoring and therapeutic programs targeted at this population.
40
He, Ling, Wei Min Sun, Yu Tian Ding, and Yu Hua Wang. "Synthesis and Photoluminescence Properties of the Novel Red Phosphor Gd2MoB2O9: Eu." Advanced Materials Research 311-313 (August 2011): 1327–31. http://dx.doi.org/10.4028/www.scientific.net/amr.311-313.1327.
Full textAbstract:
A novel phosphor, Gd2MoB2O9:Eu3+ has been synthesized by solid-state reaction and its photoluminescence in UV-VUV range are investigated. A sharp excitation band is observed in the region of 120–135 nm, which is related to the charge-transfer (CT) band of Gd3+. The broad band around 135–160 nm can be assigned to the BO3 host absorption. The broad bands around 248 nm are assigned to the CT band of Eu3+-O2-. The phosphors emit strong red luminescence centered at about 591 nm, 614 nm and 626 nm due to the5D0–7F1 and 5D0–7F2 transitions of Eu3+. The main emission peak under 254 and 147 nm excitations also shows different shifts with increasing Eu3+ concentration. This could be due to the different luminescence sites selected at high doping concentrations of Eu3+. Gd2MoB2O9:Eu3+ shows the pure red emission under both 254 and 147 nm excitations.
41
Schnittger, Susanne, Christiane Eder, Tamara Alpermann, Thomas Illig, Norman Klopp, H. Erich Wichmann, Wolfgang Kern, Claudia Haferlach, and Torsten Haferlach. "Analysis of the IDH1G105 (SNPrs11554137) Polymorphism in 961 AML Patients and in a Large Cohort of 475 Healthy Controls." Blood 118, no. 21 (November 18, 2011): 2518. http://dx.doi.org/10.1182/blood.v118.21.2518.2518.
Full textAbstract:
Abstract Abstract 2518 Introduction: Mutations in IDH1 and IHD2 at arginines 132 and 140 or 172, respectively, have recently been shown to play an important role in AML. Also the IDH1105GGT minor allele of the IDH1G105 (SNPrs11554137) polymorphism that is localized in the same exon as the IDH1R132 mutation has recently been reported to be an adverse prognostic factor in AML (JCO: 14, 2356–2364, 2010). Aim: We aimed at further delineating the frequency and impact of the IDH1105GGT minor allele in AML and also analyzed a healthy control cohort. Methods:IDH1G105 (SNPrs11554137) was analyzed in 961 AML patients by a LightCycler-based melting curve assay. Female/male ratio was 433/528 and age ranged from 13.1–100.4 years (median, 66.7 years). The results were compared to a healthy control cohort from the KORA (Cooperative Health Research in the Region of Augsburg) survey S4, which consists of 475 cases who where matched to the leukemia samples with respect to sex (193f/282m) and age (median: 67, range 32–81 years). Informed consent for participation in anonymized genetic studies was obtained from all individuals. IDH1G105 in the healthy cohort was analyzed by Sanger sequencing. Further mutation analyses were available in subsets of the AML patients, respectively, as follows: (IDH1R132 n=625, IDH2R140 n=587, IDH2R172 n=590, FLT3-ITD n=629, FLT3-TKD n=503, NPM1 n=628, CEBPA n=587, RUNX1 n=231, MLL-PTD n=629, NRAS n=273, KRAS n=133, ASXL1 n=470) and were analyzed as described previously. A subcohort of 634 AML with intermediate risk karyotype was analyzed for survival. Female/male ratio of this subcohort was 280/354 and age ranged from 15.7–86.6 years (median, 66.9 years). The adverse impact of IDH1R132, IDH2R140 and IDH2R172 on the NPM1+/FLT3-ITD- group has been shown previously for this group (Blood 2010 116: Abstract 102). Results: The IDH1105GGT minor allele was detected in 11.2% (108/961) in AML and in 8.8% (42/475) of the KORA control. This slight difference does not reach statistical significance (p=0.17) and thus there is no indication that this variance is a predisposing factor for leukemia. Also the frequency of a homozygous IDH1105GGT minor allele was not different between the AML cohort (3/108, 2.8%) and the KORA cohort (2/42, 4.8%, n.s.). In the AML cohort there was no association of the IDH1105GGT minor allele with age, WBC, platelet count or any of the above mentioned molecular mutations. In contrast, some differences in survival were observed: patients with the IDH1105GGT minor allele had a longer event free survival (EFS) than those with the IDH1105GGC major allele (median: 30.1 vs. 21.6 months, p=0.052) in the intermediate risk cohort. This prognostically favourable effect of the IDH1105GGT minor allele was most prominent in the NPM1+/FLT3- group with a median EFS of 45.1 vs 23.5 months as compared to those with the IDH1105GGC major allele (p=0.015). Conclusions: 1) The polymorphic IDH1105GGT minor allele was not found to be a marker predisposing for AML. 2) No association of the IDH1105GGT minor allele to any mutation or other biological parameters was detected. 3) We were not able to reproduce the previously published adverse impact of the IDH1105GGT minor allele on survival in AML. In contrast, in our cohort of 475 patients with intermediate risk AML the EFS was even better in patients carrying the IDH1105GGT minor allele, especially in the subcohort with NPM1+/FLT3−ITD−. Thus, we would suppose that the IDH1105GGT minor allele is a favorable molecular marker in intermediate risk AML. However, as these findings are in contrast to previously published data, further confirmation in additional studies is necessary to draw firm conclusions on the utility of the IDH1105 polymorphism as a marker for diagnostics and prognosis in AML. Disclosures: Schnittger: MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Eder:MLL Munich Leukemia Laboratory: Employment. Alpermann:MLL Munich Leukemia Laboratory: Employment. Kern:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership.
42
Durak Ediboglu, E., D. Solmaz, H. E. Oz, G. Kabadayi, H. Cinakli, E. Otman Akad, M. Ozmen, and S. Akar. "AB1155 WORK DISABILITY AND PREDICTORS OF POOR WORK OUTCOME IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1868.2–1868. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4227.
Full textAbstract:
Background:Axial spondyloarthritis (axSpA) is a chronic inflammatory disease which may lead substantial functional limitation. The disease more commonly affects men in their third decade of life. For patients with chronic disease participation in paid work may be the result of series factors like disease severity, effectiveness of the health care, availability and the type of work. Previously it was reported that ankylosing spondylitis may cause adverse work outcome.Objectives:To understand the impact of axSpA on work disability and the factors associated with poor work outcome.Methods:A cross-sectional survey was performed among323 patients withaxSpA according to ASAS classification criteriafrom one tertiary center. In total 219 (67.8%) patients were working age at the time study. The others were student, housewife or retired. Demographic, social and disease related characteristics were collected. Characteristic that might be associated with premature work loss were evaluated byunivariable and multivariable logistic regression analysis.Results:Out of 219 axSpA patients (155 [71%] r-axSpA and 64 nr-axSpA, 69% HLA-B27 positive) who have a work at least once 47 (22%) was either withdrawn from work (n=35) or retired due to disability (n=12) during median (IQR) 12 (12) years symptom duration. Demographic and disease related characteristics of the patients with or without work diasbilitywere summarized in the table. In univariate analysis gender, smoking, education levels, the presence of peripheral arthritis, BASMI score and radiographically presence of syndesmophyte and hip involvement were found to be associated with poor work outcome. However poor work outcome were similar between r- and nr-axSpA patients. In regression analysis low education level (HR:3.4 [95%CI:1.4-8.6], P=0.007), peripheral arthritis (HR:2.7[95%CI:1.07-6.8], P=0.035), and ever smoking (HR:4.9 [95%CI:1.3-18.0], P=0.02) were independent predictors of work disability.Conclusion:Our results suggest that there is still remarkable poor work outcome among axSpA patients and work disability might be similar in r- and nr-axSpA. Patients who are smoker, with low education levels, and peripheral arthritis seem to be at risk for premature work loss.Table.Demographics and diseases related characteristics of study populationVariablesAll population(n=219)No work disability(n=172)Work disability(n= 47)Male, n (%)161 (73.5)122 (70.9)39 (83)Age, years*41.5 (9.4)43.1 (12.4)Ever smoking, n (%)155 (71.4)115/171 (67.3)40/46 (87)Education duration ≤8 years, n (%)82/212 (61.3)53/165 (32.1)29/47 (61.7)Disease duration, years6.7 (8.3)5.5 (6.3)10.7 (12.6)BASDAI*4.3 (2.4)4 (2.3)5.3 (2.6)BASFI*3.4 (2.8)2.9 (2.5)5.4 (3.0)ASDAS-CRP*2.8 (1.2)2.7 (1.1)3.3 (1.4)BASMI*2.3(2.0)2 (1.8)3.5 (2.4)ASQOL*9 (5.5)8 (5.3)12 (4.9)Peripheral arthritis, n (%)81/207 (39.1)54/163 (33.1)27/44 (61.4)Hip arthritis, n (%)39/205 (19)26/163 (16)13/42 (31)Presence of syndesmophyte, n (%)92/164 (56.1)63/125 (50.4)29/39 (74.4)* Variables presented as mean (SD).Disclosure of Interests:None declared
43
Mander, J. B., M. J. N. Priestley, and R. Park. "Closure to “ Observed Stress‐Strain Behavior of Confined Concrete ” by J. B. Mander, M. J. N. Priestley, and R. Park (May, 1990, Vol. 116, No. 5)." Journal of Structural Engineering 117, no. 2 (February 1991): 628–29. http://dx.doi.org/10.1061/(asce)0733-9445(1991)117:2(628).
Full text
44
McGonigle, Glenda J., Damian P. J. Finnegan, Mary Frances McMullin, Terence R. J. Lappin, and Alexander Thompson. "HOXA6: A Novel Candidate Gene in AML." Blood 108, no. 11 (November 1, 2006): 2312. http://dx.doi.org/10.1182/blood.v108.11.2312.2312.
Full textAbstract:
Abstract Molecular classification of acute myeloid leukemia (AML) has identified several candidate genes that could potentially define prognosis and response to therapy. One such candidate, identified from microarray studies, is the Class I homeobox gene HOXA9. The HOX gene network encodes master regulators of developmental processes including hemopoiesis. To quantify the contribution of this network of genes in AML, we carried out specific RQ-PCR analysis on twenty-four de novo patient samples using a subset of genes (12 HOX and MEIS1) selected on the basis of their recently reported expression in AML. HOXA6 was ranked, as the most highly expressed gene (range 1 x 103 – 2 x 107 copies per 50 ng RNA), substantially higher than HOXA9 (see Table). Further analysis identified high expression of HOXA6 in both human myeloid cell lines and CD34+ enriched primary progenitors. Parallel studies with murine progenitors (c-Kit+, Lin−) and cell lines also showed a preponderance of Hoxa6 expression over other family members including Hoxa9 and Hoxb4. Several hemopoietic cell lines, namely Ba/F3, EML, FDCP-Mix A4 and 32Dcl3 were subsequently used to investigate Hoxa6 regulation following differentiation or growth factor stimuli. Hoxa6 expression decreased with cell differentiation and growth factor depletion/replenishment studies indicated a cell-cycle component for Hoxa6 regulation. Direct evaluation of cell-cycle status, using Hoechst 33342 staining and cell sorting, identified peak expression of Hoxa6 during S-phase. Gene deletion studies involving Hox tend to result in either a moderate or no phenotype, presumably due to intrinsic compensatory mechanisms. We therefore overexpressed HOXA6 in the Ba/F3 cell line to gain functional insights. Ba/F3-A6 cells were compared to mock-transfected and vector controls on the basis of proliferation, maturation, cell-cycle status, growth factor-dependence and apoptosis. The Ba/F3-A6 cells displayed a growth advantage over normal cells in the presence of IL-3 and maturation was not impaired. Cell-cycle analysis showed a reduction in the number of cells in both G2M and S-phase, associated with accumulation in the pre G1-phase, indicative of increased apoptosis. IL-3 depletion studies of Ba/F3-A6 cells indicated substantial factor-independent growth compared to controls, implying oncogenic potential for HOXA6. In support of this, a recent report (Mamo et al, Blood. 2006 Jul 15;108(2):622–9) indicated Hoxa6 as a potential collaborator in a Meis1-induced model of AML. Taken together these findings identify Hoxa6 as a novel candidate gene in AML with the capacity to alter growth and survival of hemopoietic cells. Gene Expression Ranking of HOX and MEIS1 in AML. GENE EXPRESSION RANGE MEAN RANK S.D. OVERALL RANK Expression values (copies per 50 ng RNA) compiled from primary AML patient samples (n=24) or * (n=12). S.D = standard deviation. HOXA6 1.2 x 103 – 1.7 x 107 2.2 1.6 1 HOXB3 9.3 x 101 – 8.4 x 106 3.2 2.5 2 HOXB2* 7.9 x 102 – 5.4 x 106 3.4 2.0 3 HOXA9 4.0 x 101 – 5.3 x 106 5.3 2.4 4 MEIS1 0.6 x 101 – 8.4 x 106 5.4 2.7 5 HOXA10* 2.4 x 102 – 1.7 x 105 5.5 3.2 6 HOXB4 1.5 x 102 – 7.8 x 105 5.5 3.2 7 HOXA7* 5.3 x 103 – 1.8 x 106 5.7 1.7 8 HOXB6 2.3 x 101 – 8.8 x 105 6.6 2.8 9 HOXA4 4.1 x 101 – 1.1 x 105 7.9 3.4 10 HOXA5* 3.4 x 101 – 4.3 x 104 9.3 2.8 11 HOXC6 1.0 x 101 – 3.2 x 103 9.7 2.3 12 HOXA11* 4.0 x 101 – 6.1 x 103 10.6 2.2 13
45
Xing, Xiao-Liang, Zhi-Yong Yao, Ti Zhang, Ning Zhu, Yuan-Wu Liu, and Jing Peng. "MicroRNA-Related Prognosis Biomarkers from High-Throughput Sequencing Data of Colorectal Cancer." BioMed Research International 2020 (September 10, 2020): 1–12. http://dx.doi.org/10.1155/2020/7905380.
Full textAbstract:
Background. Colorectal cancer (CRC) is the third most common cancer in the world, and most of them are adenocarcinomas. CRC could be classified as colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ) according to the original tumorigenesis position. Increasing evidences indicated that microRNAs (miRNAs) play an important role in the occurrence of multiple tumors. Methods. In this study, we firstly downloaded miRNA (COAD, 8 controls vs. 455 tumors; READ, 3 controls vs. 161 tumors) and mRNA (COAD, 41 controls vs. 478 tumors; READ, 10 controls vs. 166 tumors) data from The Cancer Genome Atlas (TCGA) database and then used DESeq2, RegParallel, miRDB, TargetScanHuman 7.2, DAVID 6.8, STRING, and Cytoscape software to identify the potential prognosis biomarkers. Results. We identified 175 differential expression miRNAs (DEMs) and 3747 differential expression genes (DEGs) in COAD and 184 DEMs and 3928 DEGs in READ. And then, we obtained 21 (13 in COAD and 8 in READ) DEMs associated with the survival rates, which correlated with 440 (217 in COAD and 223 in READ) overlapping DEGs. Through survival analysis for those overlapping DEGs, we found 11 (8 in COAD and 3 in READ) overlapping DGEs associated with survival rates of patients, which were correlated with 9 (7 in COAD and 2 in READ) DEMs significantly. Conclusion. In this study, we found several candidate prognostic biomarkers which have been identified in various cancers and also found several new prognosis biomarkers of COAD and READ. In conclusion, this analysis based on theoretical knowledge and clinical outcomes we have done needs further confirmation by more researches.
46
Wilson, George, Dan Martin, James P. Morton, and Graeme L. Close. "Male Flat Jockeys Do Not Display Deteriorations in Bone Density or Resting Metabolic Rate in Accordance With Race Riding Experience: Implications for RED-S." International Journal of Sport Nutrition and Exercise Metabolism 28, no. 4 (July 1, 2018): 434–39. http://dx.doi.org/10.1123/ijsnem.2017-0371.
Full textAbstract:
Despite consistent reports of poor bone health in male jockeys, it is not yet known if this is a consequence of low energy availability or lack of an osteogenic stimulus. Given the rationale that low energy availability is a contributing factor in low bone health, we tested the hypothesis that both hip and lumbar bone mineral density (BMD) should progressively worsen in accordance with the years of riding. In a cross-sectional design, male apprentice (n = 17) and senior (n = 14) jockeys (matched for body mass and fat-free mass) were assessed for hip and lumbar spine BMD, as well as both measured and predicted resting metabolic rate (RMR). Despite differences (p < .05) in years of race riding (3.4 ± 2 vs. 16.3 ± 6.8), no differences were apparent (p > .05) in hip (−0.9 ± 1.1 vs. −0.8 ± 0.7) and lumbar Z-scores (−1.3 ± 1.4 vs. −1.5 ± 1) or measured RMR (1,459 ± 160 vs. 1,500 ± 165 kcal/day) between apprentices and senior jockeys, respectively. Additionally, years of race riding did not demonstrate any significant correlations (p > .05) with either hip or lumbar spine BMD. Measured RMR was also not different (p > .05) from predicted RMR in either apprentice (1,520 ± 44 kcal/day) or senior jockeys (1,505 ± 70 kcal/day). When considered with previously published data examining underreporting of energy intake and direct assessments of energy expenditure, we suggest that low BMD in jockeys is not due to low energy availability per se but rather the lack of an osteogenic stimulus associated with riding.
47
Saffari, Niloufar, Mieke Koehoorn, Kimberlyn McGrail, and Christopher B. McLeod. "O7A.2 Gender, immigration status, and work disability for acute injuries." Occupational and Environmental Medicine 76, Suppl 1 (April 2019): A61.2—A61. http://dx.doi.org/10.1136/oem-2019-epi.164.
Full textAbstract:
BackgroundThe nature of work is changing rapidly with precarious work emerging as an occupational health issue. Both immigration status and gender are associated with precarious work and health inequalities. This paper investigated the modifying effect of gender on the relationship between immigration status and work disability duration for acute injuries in the Canadian context.MethodsWorkers in the Canadian jurisdiction of British Columbia with a workers’ compensation claim from 1995 to 2012 were linked to immigration data (n=8 83 830 claims), and categorized as recent (<10 years, 6.7%) or established immigrants (10+years, 4.0%), versus Canadian-born (89.3%). Work disability days one-year post-injury were modeled using quantile regression, adjusted for confounders and stratified by gender (29.6% women). The analyses was restricted to fractures (n=55 324 claims, 19.4% women), a ‘visible’ injury with a prescribed treatment trajectory within a public health care system.ResultsDisability duration for a work-related fracture was significantly longer for immigrant workers compared to Canadian–born workers regardless of immigration timing or gender, across the disability distribution: 7 to 10 days longer at the 25th percentile [e.g. recent immigrant women 10.4 [95% CI 5.6, 15.2] and men 8.9 days [6.8, 10.9]]; 12 to 15 days longer at the 50th percentile [e.g. recent immigrant women 15.3 [8.0, 22.7] and men 15.6 [12.5, 18.8]]; and 22 to 26 days longer at the 75th percentile [e.g. established immigrant women 22.5 [9.4, 35.8] and men 21.9 [13.4–30.3]].DiscussionLonger disabilities durations for fractures suggest that health inequalities and work vulnerabilities for immigrant workers are not readily explained by subjective injury characteristics or variability in clinical treatment guidelines. The current findings informed two research initiatives to investigate precarious employment on worker health, and to identity policy levers to mitigate inequalities.
48
Schultz, Nicolai Aagaard, Ib Jarle Christensen, Jens Werner, Nathalia Giese, Benny Vittrup Jensen, Ole Larsen, Jon Kroll Bjerregaard, et al. "Pretreatment plasma concentrations of YKL-40 and IL-6 in patients with pancreatic cancer: Potential diagnostic and prognostic biomarkers." Journal of Clinical Oncology 31, no. 4_suppl (February 1, 2013): 164. http://dx.doi.org/10.1200/jco.2013.31.4_suppl.164.
Full textAbstract:
164 Background: To test the hypothesis that high pretreatment plasma YKL-40 and IL-6 associate with pancreatic cancer (PC) and short overall survival (OS). Methods: 556 patients with PC from Denmark (N=445) and Germany (N=111) were included in the present prospective biomarker study. 152 (27%) patients were operated and treated postoperative with adjuvant gemcitabine. 404 (73%) had locally advanced or metastatic PC and received palliative chemotherapy (primarily gemcitabine). Pretreatment plasma YKL-40 and IL-6 were determined by ELISA with known reference intervals in healthy subjects. Results: The OR for prediction of PC in the whole study population was significant for all 3 biomarkers with CA 19-9 having the highest AUC (YKL-40: OR=4.50, 95% CI 3.99-5.08, p<0.0001, AUC=0.87; IL-6: OR=3.68, 3.08-4.44, p<0.0001, AUC=0.87; CA 19-9: OR=2.28, 1.97-2.68, p<0.0001, AUC=0.93). YKL-40, IL-6 and CA-19-9 increased with more advanced stage (YKL-40 median (IQR): Stage IA-IIA 100 (68-157), IIB-III 101 (59-179), IV 166 (89-296) μg/L, p<0.0001; IL-6: Stage IA-IIA 4.2 (1.9-8.9), IIB-III 4.0 (2.1-8.2), IV 7.4 (3.6-18) ng/L, p<0.0001); CA-19-9: Stage IA-IIA 58 (10-622), IIB-III 209 (54-856), IV 1041 (146-9178) ng/L, p<0.0001). Univariate Cox analysis in resected patients showed that only pretreatment IL-6 and CA 19-9 (dichotomized according to normal values) were associated with short OS (YKL-40: HR=1.38, 0.87-2.18, p=0.17; IL: HR=2.23, 1.41-3.52, p=0.0006; CA 19-9: HR=2.80, 1.54-5.09, p=0.0007). In non-resectable patients all 3 biomarkers were associated with short OS (YKL-40: HR=1.54, 1.23-1.93, p=0.0001; IL: HR=1.63, 1.29-2.06, p<0.0001; CA 19-9: HR=1.48, 1.02-2.15, p=0.039). Multivariate Cox analysis in non-resectable patients (YKL-40, IL-6, CA 19-9 (log transformed base 2), age, sex, and stage) demonstrated that YKL-40 (HR=1.12, 1.02-1.23, p=0.021), IL-6 (HR=1.20, 1.09-1.31, p=0.0001) and CA 19-9 (HR=1.10, 1.07-1.14, p<0.0001) were independent biomarkers for short OS. This was not found in resected patients. Conclusions: Pretreatment plasma concentrations of YKL-40 and IL-6 may be new diagnostic and prognostic biomarkers in patients with PC.
49
Mattson, David L. "Long-term measurement of arterial blood pressure in conscious mice." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 274, no. 2 (February 1, 1998): R564—R570. http://dx.doi.org/10.1152/ajpregu.1998.274.2.r564.
Full textAbstract:
This study describes a technique for the direct daily measurement of arterial blood pressure, sampling of arterial blood, and continuous intravenous infusion in free-moving, conscious, Swiss-Webster mice. Catheters were chronically implanted in the femoral artery and vein, tunneled subcutaneously, exteriorized at the back of the neck in a lightweight tethering spring, and attached to a swivel device at the top of the cage. Time-control experiments ( n = 8) demonstrated stable values of mean arterial pressure (MAP, 116 ± 1 mmHg) and heart rate (HR, 627 ± 21 beats/min) for up to 35 days after catheter implantation. It was further observed that restraining mice ( n = 7) increased MAP by 10 ± 3 mmHg and HR by 78 ± 8 beats/min from the values observed under free-moving conditions. To demonstrate the chronic use of the venous catheter, intravenous infusion of N G-nitro-l-arginine methyl ester (l-NAME, 8.6 mg ⋅ kg−1 ⋅ day−1, n = 6) for 5 days significantly increased MAP from 117 ± 4 to 131 ± 4 mmHg without altering HR. In a final group of mice ( n = 5), orall-arginine (2% in drinking water) increased plasma arginine concentration from 90 ± 7 to 131 ± 17 μM and preventedl-NAME hypertension. These experiments illustrate the feasibility of long-term intravenous infusion, direct arterial blood pressure measurements, and arterial blood sampling in conscious mice.
50
Mesquita, L. G., F. Perecin, P. R. Adona, C. L. V. Leal, L. C. Smith, and F. V. Meirelles. "163 DEVELOPMENT OUTCOME AND MITOCHONDRIAL MEMBRANE POTENTIAL IN BOVINE PARTHENOTES SUBMITTED TO MITOCHONDRIAL SUPPLEMENTATION AND DEPLETION AT THE 1-CELL STAGE." Reproduction, Fertility and Development 22, no. 1 (2010): 240. http://dx.doi.org/10.1071/rdv22n1ab163.
Full textAbstract:
Apart from supplying ATP for cellular function by establishing a proton gradient across the inner membrane (Ψmm), mitochondria also play a central role in death pathways of most cells in the organism. Since mitochondria undergo major transformations during early embryogenesis, we hypothesize that the amount of these organelles at the 1-cell stage is correlated to development. Herein we evaluated the impact of mitochondrial supplementation and depletion on embryonic development and Ψmm. Immature oocytes were collected from ovaries of slaughtered cows and submitted to in vitro maturation for 26 h and parthenogenetically activated by 5 min exposure to 5 μM ionomycin followed by 3 h culture in 2 mM 6-DMAP (control, C). In order to deplete mitochondria (depletion, D), zygotes were centrifuged (15 min 10,000g in HEPES-SOF with cytochalasin B) and the mitochondria, at the mitochondria-enriched cytoplast fraction (MECF), were partially removed by micro-manipulation. Mitochondria supplementation was performed by introducing the MECF from the depleted zygote into another zygote (supplemented, S). Centrifugation and cytoplasm removal effects (7.1% of volume) were tested using 2 other control groups: centrifuged zygotes (centrifuged control, CC) and aspirated zygotes (aspirated control, AC). Embryos were submitted to Mitotracker CMXRos (500 ηM) staining to measure Ψmm levels. Zygotes were cultured in SOF medium for 3, 72, and 168 h in 5% O2, 5% CO2, and 90% N2. Blastocysts were fixed and stained with Hoechst 33342 to count nuclei. At 72 h, development to the 8-cell stage was reduced in CC (41.6%), D (37.0%), and S (33.2%) groups when compared to C (52.5%) and AC (49.3%) control groups (P < 0.05, chi-square). Similar findings were observed at 168 h where the CC (31.9%), D (21.0%), and S (19.1%) group showed reduced development to the blastocyst stage when compared to the C (40.5%) and AC (41.8) control groups (P > 0.05, chi-square). Moreover, nuclear number was significantly reduced in the D (101.6 ± 12.4) and S (102.2 ± 7.8) groups when compared to the C (137.9 ± 6.7) and CC (126.6 ± 7.4) controls. The AC group (112.2 ± 7.8) is similar to CC, D, and S. These results indicate a sensitivity of embryos to changes (i.e. supplementation and depletion) in the number of mitochondria present at the 1-cell stage on further development to the 8-cell and blastocyst stages. With the exception of Ψmm of AC blastocysts at 168 (62.8 ± 6.8, P < 0.05; the Tuckey test), all other controls and treated blastocysts showed similar Ψmm levels (100.0 ± 6.2; 84.1 ± 8.3; 85.9 ± 6.6; 97.1 ± 19.1, respectively for C, CC, D, and S groups). Although, these results indicate that the Ψmm is not affected by the removal or addition of mitochondria. A reduction in cytoplasm volume (only the AC group) seems to adversely affect the ability of mitochondria to sustain normal Φmm levels at the blastocyst stage without affecting development or nuclear number. Together, supplementation and depletion of MECF are detrimental to development through mechanisms independent of mitochondrial Ψmm. Financial support: FAPESP-Brazil.